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AUTOIMMUNE DISEASES 
The immune system is an extraordinary integrated network of chemical and cellular mediators, 
delegated to the organism defense against any form of external agent. As summarized in Figure 1, 
under normal conditions the immune system exhibits tolerance to self-molecules, and thus does 
not respond to elements expressed in endogenous tissues. When self-tolerance is lost, the immune 
system reacts against one or more of the body’s own components, triggering a set of mechanisms 
that represent the hallmark of autoimmune diseases (AID).  
 
Figure 1: Central and Peripheral Tolerance Mechanisms1.  
 
AID are a collection of many complex and heterogeneous disorders, characterized by the aberrant 
reaction of the immune system against self. Such pathologies are classified as organ-specific, in 
which the immune response is predominantly or exclusively directed toward tissue-specific 
elements, or systemic, in which the loss of immune tolerance is directed toward systemic antigens 
(Ag) and disease manifestations can occur at a variety of different sites. It is estimated that AID 
afflict more than 8% of people worldwide2, but the actual prevalence is predicted to be even higher 
because the extent of less common AID is possibly miscalculated due to the scarcity of 
epidemiological data3. Nearly 75% of AID patients (pts) are women3, and the risk of developing an 
AID is about tenfold higher for women than for age-matched men, although there are exceptions 
(e.g. several autoimmune renal disorder)4.  
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Even if the etiology of AID is still unknown, it is widely demonstrated that both onset and 
development are consequence of interaction between genetic and environmental factors5. It is 
known for decades that genetic predisposition to most AID involves genes within the major 
histocompatibility complex (MHC), reflecting the essential immunoregulatory effects of the human 
leukocyte Ag (HLA), but the exact mechanism that underlie these effects is still matter of debate. 
Recently, genome-wide association studies (GWAS) permitted to take remarkable steps forward in 
the genetics of AID: it was shown that more than 200 loci are associated with one or more AID. In 
many cases, the precise causal alleles or genes driving the associations were not identified, but it 
was demonstrated that some loci belong to categories of genes involved in: intracellular signaling 
regulating T- and B-cells activation; signaling by cytokines and cytokines receptors; pathways 
mediating innate immunity and microbial response1. Despite these recent progresses, much of the 
heritability of AID remains unaccounted for, disclosing that genes, alone, are not sufficient to 
trigger the disease, and that environmental factors play a key role in the autoimmune process. This 
hypothesis is supported by the largely incomplete concordance of AID in monozygotic twins6. 
Environmental risk factors associated with AID are numerous, as well as their possible mechanisms 
of action (summarized in Figure 2). In particular, both chemical and infectious agents are able to 
induce aberrant post-translational modifications (PTM) in self-Ag, contributing to tolerance 
breakdown. 
 
Figure 2: Environmental factors associated with AID and putative mechanisms  
involved in the breakdown of immune tolerance7. 
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Role of aberrant post translational modifications in 
autoimmunity 
As just mentioned, it was demonstrated that one of the mechanisms able to elicit the autoimmune 
reaction is represented by PTM, described as covalent addition of functional groups, or amino acids 
(Aa) conversions, that can be driven by enzymes or occur spontaneously (Table 1)8,9. PTM are 
frequently required for the biological function of numerous proteins, and occur during many 
physiological cellular events, e.g. ageing and cell replication: indeed, it is estimated that 50-90% of 
the human proteins are post-translationally modified9. The presence of aberrant PTM can result to 
changes in both functionality and immunogenicity of the protein, leading to the formation of neo-
Ag. Effectively, PTM could induce immune tolerance breakdown through different mechanisms. 
Concerning T-cells autoimmune response, some PTM could not be present at the time of selection 
within the thymus, allowing autoreactive T-cells to migrate to the periphery, or else, proteins 
containing PTM could encounter a different Ag processing compared with the unmodified analog 
(Figure 3). In any case, T-cells response leans toward specificity to the modified self-Ag10. 
Conversely, B-cells response tends to be promiscuous, since antibodies (Ab) could be able to bind 
not only the modified but also the native self-Ag, leading to cross-reactivity. This is probably due to 
the conservation of the Aa flanking the modified site10. 
Modification Aa altered 
Additions  
Acetylation Lys, Ser 
Glycosylation Asn, Ser 
Hydroxylation Pro, Lys 
Methylation Arg, Hys, Lys 
Phosphorilation Ser, Thr, Tyr 
Conversions  
Deamidation/Isoaspartylation Asp, Asn 
Citrullination/Deamidation Arg 
 
Table 1. Example of common PTM. 
 
 
Figure 3: alteration of Ag processing by aberrant PTM. (A) Native proteins are cleaved by 
proteases (represented by X) into peptides. T and B cells do not recognize self-peptides. (B) 
Proteins bearing aberrant PTM are not properly cleaved by proteases, 
 creating neo-Ag for T cells 11. 
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The differences between T- and B-response to post-translationally modified self-proteins was 
elucidated by Mamula M.J. et al.12, in a study on the Ag of human systemic lupus erythematosus 
(SLE), the small nuclear ribonucleoprotein particle D. The authors showed that mice immunized 
with isoaspartyl-modified form (isoAsp) of the peptide Ag develop T-response only against isoAsp 
peptide, and not against the Asp form. On the other hand, auto-Ab generated by the same 
immunization procedure were able to bind both isoAsp and Asp form of the Ag. Therefore, it could 
be hypothesized that the introduction of an aberrant PTM is able to promote the epitope spreading 
process, by which the immune response diversifies to include epitopes beyond the site(s) inducing 
the initial reaction13. This phenomenon can be both intra-molecular and inter-molecular12,14. 
In a nutshell, a putative PTM-induced autoimmune mechanism could be the following (Figure 4): 
proteins are aberrantly post-translationally modified e.g. during cellular stress, and then are 
released from apoptotic/necrotic cells where they are phagocytized by Ag presenting cells (APC). 
The presence of PTM can affect the Ag processing and presentation on MHC class II. At that point, 
modified peptide is presented to autoreactive T- and B-cells that have escaped negative selection, 
leading to autoimmune response11. 
 
Figure 4. Aberrant PTM on self-proteins initiate the autoimmune response. 
 
Relevance of biomarkers in autoimmunity 
AID are generally thought as being relatively rare2, but actually are among the leading causes of 
death among young and middle-aged women (age < 65 years) in the United States15. The chronic 
nature of many AID results in a significant impact in terms of quality of life, medical care utilization, 
and both direct and indirect economic costs16. Therefore, it is crucial to carry out an early diagnosis 
and to follow the progress of the disease, ideally with a test characterized by low-invasivity, low-
cost, and easy execution. Unfortunately, to date, in most cases the diagnostic and prognostic 
methods used for AID do not meet these criteria.  
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In order to develop a diagnostic or prognostic tool able to satisfy the previously mentioned 
properties, it could be useful to take advantage of biomarkers (BM), objectively measurable and 
evaluable biological indicator of normal physiological events, pathogenic processes or 
pharmacological responses to a therapeutic intervention. Indeed, BM can provide numerous 
information about the disease of interest, reflecting and summarizing easily all the complex agents 
and processes that are needed to produce it17. This reduction of biological complexity makes BM 
important and strong “decision-making tools” in clinical and diagnostic18. Consequently, BM field 
is arousing great attention, and both diagnostic and prognostic research is moving toward the 
design of methodologies that allow the simultaneous measurement of multiple markers (the so-
called “profiling methods”), in order to have a more comprehensive view and to follow different 
aspects of the disease.  
As already noted, the autoimmune mechanism is characterized by the presence of a response 
against self-proteins, which could lead to the appearance of circulating auto-Ab. Interestingly, 
several studies showed that some disease-specific auto-Ab can precede clinical symptoms by 
years19,20, while others can fluctuate with disease exacerbations or remissions21 (as summarized in 
Figure 522). In such cases, auto-Ab may represent useful and valuable BM for both diagnostic and 
prognostic purposes. One of the greatest advantages in using auto-Ab as disease BM is exemplified 
by the possibility to detect them in biological fluids with simple immunoenzymatic assays, using 
antigenic probes consisting of the native Ag, or molecules able to mimic its structure. In the latter 
case, it is essential not only to identify the biological target(s) of auto-Ab, but also to produce 
suitable probes. 
 
 
Figure 5: Potential role of Ab as biomarkers  
in the case of central nervous system demyelinating AID. 
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Strategies for antigenic probes production: recombinant versus 
synthetic 
The antigenic probe source is a crucial variable, as it affects reproducibility, specificity and 
sensitivity of the detection assay. The necessity to satisfy these criteria makes difficult to use native 
Ag isolated from natural sources (e.g. animal tissues), because of their significant limitations in 
terms of yield, purity and reproducibility. Therefore, it is essential to overcome this problem 
identifying an antigenic probe able to mimic the native Ag and to detect specific auto-Ab. 
One of the most used strategies to produce antigenic probes is represented by the molecular 
cloning of the auto-Ag. This procedure consists in the isolation of the messenger RNA (mRNA) 
corresponding to the gene of interest, the conversion of mRNA to complementary DNA (cDNA) by 
reverse transcriptase and the insertion of the cDNA in an expression vector. Then the obtained 
vector is transferred in the selected expression host, which will produce the recombinant protein 
encoded by the cloned gene (Figure 6). The choice of the expression host is decisive to obtain the 
protein provided with the desired physicochemical characteristics. For example, Escherichia coli 
(E.coli) represents a very efficient protein production machinery, which permits to achieve a stable, 
easy and relatively low-cost recombinant protein production. Furthermore, the use of inducible 
promoter expression plasmids allows to obtain large amounts of product. The recombinant protein 
can be easily purified by affinity chromatography adding an N- or C-terminus-tag (e.g. 6 residues 
of Histidine, 6-His): this technique enables to obtain highly purified final products, and also to 
perform on-column reactions, as cleavage to remove the tag or refolding.  
 
Figure 6: Outline of molecular cloning in bacteria. 
 
However, the use of E.coli as expression host has some limitations. First, the size of the protein 
should be comprised within the range of 100-300 Aa. Larger proteins are poorly expressed, while 
smaller need to be stabilized by a fusion partner. Second, bacteria often recognize the recombinant 
protein as foreign, and therefore isolate it into inclusion bodies (IB), insoluble aggregates of 
misfolded, neo-synthesized recombinant protein. The purification of the protein from IB requires 
a time-consuming procedure that includes sonication, mechanical and/or physical 
homogenization, and the use of strong denaturant conditions (e.g. 6 M Urea or Guanidinium 
Hydrochloride, GuaCl). Moreover, since the protein folding is often fundamental for the Ag-Ab 
recognition, the recombinant probe has to be refolded at a later stage. However, the IB expression 
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can be considered also a kind of advantage: IB are often formed only by the protein, are non-toxic 
for the host and can be accumulated in the cytoplasm in larger amounts compared with soluble 
proteins. Third, recombinant proteins expressed in bacteria are lacking in PTM, because the 
biological machinery required for the modification process is absent in prokaryotes. In the last few 
years, some advanced molecular biology techniques were developed to overcome this issue. In 
particular, the attention was focused on transferring bacteria N-glycosylation systems to expressing 
E.coli strains, allowing the in vivo production of glycosylated proteins in an easy-to-manipulate 
and fast-growing host23. In 2002 Wacker et al.24 discovered an N-linked glycosylation system in 
Campylobacter jejuni (C. jejuni), a Gram-negative bacterium, and fully reconstituted this pathway 
in E.coli. The C. jejuni glycosylation machinery is based on a block transfer mechanism, which 
involves the addition of an undecaprenyl pyrophosphate-linked heptasaccharide to the amino 
group of an Asn in the protein consensus sequence Asp/Glu-X1-Asn-X2-Ser/Thr (X1 and X2 are 
any amino acid except Pro)25,26 (Figure 7a). The oligosaccharide is assembled in the cytosol by the 
addition of the indicated sugars from nucleotide-activated donors, and is subsequently translocated 
across the inner membrane into the periplasm by the protein glycosylation K protein. Another N-
glycosylation system was defined in the Gram-negative gammaproteobacterium Haemophilus 
influenzae (H. influenzae), providing the sequential transfer of sugars to the conventional 
eukaryotic consensus sequence for N-linked glycosylation27,28 (Figure 7b). In particular, it was 
disclosed that sugars from nucleotide-activated donors are transferred to the Asn-X-Ser/Thr 
sequon of high-molecular-weight adhesin 1 (HMW1) by the glycosyltransferase HMW1C in the 
cytoplasm, and are elongated by the same enzyme. This mechanism was confirmed with purified 
components in vitro, demonstrating the ability of HMW1C to transfer both glucose and galactose 
residues derived from common sugar precursors. Furthermore, it was shown that HMW1C exhibits 
both oligosaccharyltransferase activity, adding N-linked sugars to HMW1, and glycosyltransferase 
activity, generating hexose–hexose bonds. Even if these in vivo glycosylation methods are still quite 
challenging, they open up the possibility to produce proteins provided with the desired glycans 
using molecular cloning tools29. 
 
Figure 7: Overview of bacterial N-linked pathways for protein glycosylation.  
a) Block transfer (C. jejuni) and b) Sequential transfer (H. influenzae). 
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In addition to the bacteria system, also numerous eukaryotic expression systems are yet available 
(yeast, plants, insects and mammalian). These methodologies allow the obtainment of proteins 
provided with the host usual PTM, which may not correspond to the desired one. Compared with 
the bacteria system, yields are often lower, costs of production are higher and cell culturing is 
noticeably more complicated. 
Another methodology used to produce antigenic probes is represented by the synthesis of 
peptides, short chains of Aa linked by amide bond. The most widely used technique to obtain 
peptides is solid-phase peptide synthesis (SPPS), which consists in the elongation of a peptide chain 
anchored to a solid matrix by successive additions of Aa, taking advantage of the formation of an 
amide bond between the carboxyl group of the incoming Aa and the amino group of the Aa bound 
to the matrix. The procedure can be fully automated. The presence of a covalent bond between the 
growing chain and the support permits an easy separation of the peptide from any excess of unused 
Aa and other by-products. Peptides are stable in time, and by SPPS they can be obtained in large 
amount, with high purity and reproducibility, using a rather simple procedures. SPPS represent a 
promising tool for antigenic probes production, essentially for two reasons: 
 It can be used to obtain peptides containing both linear and conformational epitopes; 
 It allows the univocal inclusion of the desired PTM in the peptide, using both a building 
block and a convergent approach.  
On the other hand, there are several drawbacks: 
 Peptides are designed according to the native auto-Ag, and then it is mandatory to identify 
the exact Aa sequence of interest; 
 The size of the molecules accessible by this technique is limited (up to 50 Aa); 
 Peptides with incorrect, truncated or modified sequences can occur due to technical failure; 
 Peptide separation and characterization methods are required. 
A methodology inspired by the necessity to overcome some of the synthetic and recombinant 
approaches issues is the native chemical ligation (NCL), a chemoselective reaction between a 
C-terminal thioester and an N-terminal Cys residue to produce a peptide bond at the site of ligation 
(Figure 8)30. The first step is a transthioesterification between the thiol side-chain of the Cys and 
the C-terminal acyl donor to generate an intermediate thioester-linked adduct; then a spontaneous 
intramolecular S→N acyl shift produces a native amide bond between the two fragments. NCL 
allows to introduce the desired modification in a controlled fashion in the C-terminal peptide 
fragment, which subsequently will be connected with the N-terminal recombinant portion. The 
ligation occurs specifically at the N-terminal Cys, even if additional Cys residues are present in 
either segment, and no protecting groups are necessary for any of the Aa side-chain functional 
groups31. The NCL reaction is performed in aqueous solution, and chaotropes as GuaCl or Urea can 
be added to increase the solubility of the fragments without affecting the success of the ligation.  
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Figure 8: Native Chemical Ligation scheme 
 
NCL can be carried out using two unprotected peptide fragments, or a peptide and a recombinant 
protein. The latter strategy enables to obtain larger proteins, and requires (1) a recombinant protein 
provided with an N-terminal free Cys, and (2) a synthetic peptide with a C-terminal thioester, 
prepared according to the specifications reported below: 
(1) To produce a recombinant protein with an N-terminal free Cys, it is necessary to introduce 
a pre-Cys sequence that will be proteolitically cleaved after the protein purification. One of 
the most commonly used technique to produce the free-Cys involves the use of Tobacco 
Etch Virus (TEV) protease, a highly specific Cys endopeptidase able to recognize an 
ENLYFQ\S (where ‘\’ denotes the cleaved peptide bond) consensus sequence. The 
recombinant cleavage represents a key step, and therefore has to be optimized to obtain the 
maximum amount of pure, N-terminal free Cys protein. 
(2) The obtainment of C-terminal thioester is a critical step, which can be accomplished using 
SPPS and avoiding basic conditions that destabilize the thioester group. The efficiency of 
NCL reaction is heavily dependent on the nature of the C-terminal thioester acyl donor 
(Xaa-SR). Even if it was reported that all the 20 natural Aa are compatible with the NCL 
reaction, the kinetics depends on the steric and electronic properties of the C-terminal 
residue Xaa32.  
This NCL variant is a laborious, time-consuming method, because it requires mastery of both SPPS 
and molecular cloning, and then includes the disadvantages of either. Nevertheless, NCL combines 
also the benefits of the previously mentioned techniques, and is one of the few approaches enabling 
the obtainment of homogeneous and consistent samples of full-length protein provided with the 
modification of interest. 
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Strategies for auto-Ab detection: Enzyme-Linked ImmunoSorbent 
Assays (ELISA) 
Enzyme-linked immunosorbent assays (ELISA) are biochemical plate-based assays designed for 
detecting and quantifying substances in a given sample, based on the primary immunology concept 
of Ag binding to specific Ab. ELISA are widely used in diagnostic field and analytical biomedical 
research, as they allow both quantitative and qualitative detection of specific Ag or Ab in biological 
fluids. The greatest advantage of these techniques lies in the immobilization of one of the reactants 
to a solid surface: this feature makes ELISA easy to design and to perform, and enables to separate 
bound from non-bound material during the assay, allowing to measure specific analytes within a 
crude preparation. 
The general ELISA procedure (shown in Figure 9) involves the immobilization of the Ag on a solid 
phase (coating), usually on a 96-well microtiter plate, and the consequent blocking of any un-coated 
areas of the well with a solution of non-reactive protein (e.g. fetal bovine serum, FBS). Then the 
given biological sample is applied, allowing the binding of the coated Ag to a specific Ab, which is 
subsequently detected bound by a secondary enzyme-coupled Ab. Detection is accomplished by 
assessing the conjugated enzyme activity via incubation with a substrate to produce a measureable 
product. Secondary Ab are commonly labeled with alkaline phosphatase or horseradish peroxidase, 
and a large selection of substrates is available. The choice depends upon the required assay 
sensitivity and the instrumentation available for signal-detection. 
 
Figure 9: General ELISA technique summary33. 
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Starting from ELISA basic procedure, numerous variations of the assay were developed (Figure 10): 
 Direct assay (the Ag is detected by a labeled primary Ab). 
 Solid-phase (SP-ELISA), or direct assay (the Ag is detected using a conjugate secondary Ab, 
which binds the primary Ab). This variation represents the best compromise between ease 
of execution, costs and reliability of the results. 
 Capture assay, or sandwich ELISA (the Ag is bound between two primary Ab, one of which 
is coated on the plate. Detection occurs using a conjugate secondary Ab). 
 Competitive ELISA (primary Ab is incubated with the Ag, and the resulting complexes are 
added to wells coated with the same Ag, or with another Ag). 
 
Figure 10: ELISA variations. 
 
Chemical Reverse Approach applied to Multiple Sclerosis: 
CSF114(Glc) 
The necessity to identify new candidate BM of disease in AID led to the use of new discovery tools. 
A promising strategy to detect auto-Ab as disease-specific BM is represented by the chemical 
reverse approach, a methodology based on the use of pts sera to screen focused libraries of Ag18. 
The approach is defined “reverse” because it enables the identification of auto-Ag through the 
ELISA screening of dedicated antigenic probes libraries with a large group of pts sera. The 
recognition of specific probes by serum Ab drives the selection and the optimization of the 
“chemical” structure of the library, e.g. through the evaluation of different PTM. By the use of the 
chemical reverse approach it is possible to identify molecules able to recognize selectively and 
specifically auto-Ab as disease BM, and therefore to develop diagnostic and/or prognostic tools.  
The chemical reverse approach proved to be interesting in the case of Multiple Sclerosis (MS), 
allowing the identification of the N-glucosylated peptide CSF114(Glc) as antigenic probe, able to 
recognize disease-specific auto-Ab as BM of MS. This finding is based on the previous results 
achieved by Mazzucco et al., which demonstrated that a glucosylated peptide analogue of the 
immunodominant epitope of human Myelin Oligodendrocyte Glycoprotein (hMOG), 
[Asn31(Glc)]hMOG(30-50), is able to recognize auto-Ab in MS pts sera34. Subsequently, it was 
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demonstrated that the un-glucosylated analogue hMOG(30-50) is inactive, despite its 
conformation in solution is similar to the one adopted by [Asn31(Glc)]hMOG(30-50). Therefore, 
the authors concluded that the ability of [Asn31(Glc)]hMOG(30-50) to detect auto-Ab is not 
conformation-dependent, but is related to the N-glucose moiety35. Starting from this point, our 
research group synthesized a series of peptides and glycopeptide sequences unrelated to MOG to 
further investigate the relevance of glycosylation in MS autoimmunity36,37. We found out that all 
glycopeptides containing glucose identified high Ab titers, but that a completely MOG-unrelated 
sequence, termed CSF114(Glc), was able to detect the highest auto-Ab titers in MS pts serum. 
CSF114(Glc) is a structure-based designed type I’ -turn sequence, characterized by the propensity 
to optimally expose the sugar moiety38. The relevance of glucose was confirmed testing a small 
focused library of CSF114 analogues with glyco-Aa diversity, as glycopeptides lacking Asn(Glc) 
displayed irrelevant inhibitory activity in competitive ELISA and failed to detect IgG in SP-ELISA. 
Therefore, it was assumed that the minimal epitope is represented by Asn(Glc). Furthermore, 
through the use of another peptides library, it was also demonstrated the importance of type I’ -
turn structure for minimal epitope exposure. At the clinical level, the CSF114(Glc) value was 
established testing it as antigenic probe in SP-ELISA. It was shown that CSF114(Glc) is able to 
detect high titer IgM in 30% of the examined relapsing-remitting subtype MS population compared 
with healthy and pathological controls. Conversely, the anti-CSF114(Glc) IgG determination has a 
prognostic value, as it parallels the occurrence of magnetic resonance imaging lesions and disease 
progression in 40% of analyzed pts. These findings on CSF114(Glc) uncovered the importance of 
N-glucosylation in the case of MS immunopathogenesis, paving the way for further investigation 
on the link between this aberrant PTM and AID.  
The interest in CSF114(Glc) was boosted by the hypothesis of a mimicry between the peptide and 
aberrantly N-glucosylated self-Ag, triggering the MS specific immunological response. In order to 
identify the native Ag mimicked by CSF114(Glc), we used anti-CSF114(Glc) auto-Ab isolated from 
MS pts sera as primary Ab in Western Blot (WB) experiments on whole rat brain proteins. 
Immunoreactive bands were identified with alpha fodrin, alpha actinin 1, creatine kinase, and 
CNPase by proteomic analyses. CSF114(Glc) purified auto-Ab were subsequently tested against the 
commercially available version of the previously mentioned proteins, disclosing that only alpha 
actinin 1 was specifically recognized, whereas the other three proteins were not consistently 
detectable. It is interesting to note that alpha actinin 1 is implicated in other inflammatory and 
degenerative AID, such as lupus nephritis and autoimmune hepatitis39. These results give grounds 
for additional studies on the role of alpha actinin 1 in MS40 §.  
                                                          
§ Pandey, S., Dioni, I., Lambardi, D., Real-Fernandez, F., Peroni, E., Pacini, G., Lolli, F., Seraglia, R., 
Papini, A. M., Rovero, P. Alpha actinin is specifically recognized by Multiple Sclerosis autoantibodies 
isolated using an N-glucosylated peptide epitope. Mol. Cell. Proteomics 12, 277–82 (2013).  
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AIM OF THE WORK 
AID represent a group of chronic and heterogeneous diseases, whose common trait is the immune 
system reaction against self-components of the organism. Most of the AID have unknown etiology, 
but it was demonstrated that both genetic and environmental factors are involved in triggering the 
pathologic mechanism5. Because of their chronicity and their debilitating complications, AID have 
high medical and socioeconomic costs16, leading to the crucial necessity to perform an early 
diagnosis and to monitor the disease follow up. Unfortunately, the available diagnostic and 
prognostic instruments are often complicated and invasive. In order to develop diagnostic and/or 
prognostic tools marked by low-invasivity, low-cost, and easy execution, it is crucial to detect 
trustworthy BM. The BM characterization has a significant importance also because it represents a 
powerful instrument to disclose the molecular mechanisms involved in the ethiopathogenesis of 
the disorder of interest. 
In this context, the main goal of this work is to identify the target(s) of the humoral autoimmune 
response using the chemical reverse approach, which involves the screening of focused Ag libraries 
with pts serum18. Indeed, in the case of autoimmunity, an easily detectable and reliable BM may be 
represented by the titer of a specific auto-Ab. A key feature of this study is the evaluation of the role 
of aberrant PTM in autoimmunity, as it was hypothesized that environmental agents may induce 
the occurrence of non-natural PTM on self-proteins, uncovering neo-epitopes and triggering the 
autoimmune response11. 
For this purpose, the experimental workflow of this project is the following: 
1. Auto-Ag selection: the Ag to be studied was chosen through an in-depth bibliographical 
research on the AID of interest.  
2. Evaluation of putative aberrant PTM: depending on Ag structure, Aa sequence and 
localization, it is possible to hypothesize the most probable aberrant PTM. The eventual 
involvement of disease-correlated enzymatic reactions and the presence of modifications 
dependent on exposure to environmental agents were taken into account.  
3. Antigenic probe production: once the native Ag is known, and the presence of aberrant PTM 
was evaluated, one has to select the best strategy to produce an antigenic probe able to 
mimic the desired Ag. The selection is guided by the characteristics of the antigenic probe 
(e.g. presence of PTM, protein length, importance of folding, Aa sequence, etc.). In this 
project, depending on the characteristic of the desired antigenic probe, different 
approaches were used to produce it: SPPS, NCL and molecular cloning.  
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4. Auto-Ab detection: according to the chemical reverse approach, the obtained antigenic 
probes were tested with pts sera or with sera from animal models of the disease of interest, 
in order to verify their ability to reveal auto-Ab as specific pathological BM. The selected 
detection methodology is SP-ELISA, which is characterized by adequate specificity and 
reproducibility as well as ease of execution and moderate cost. 
 
 
In particular, the attention was focused on two main topics, which will be treated separately 
within this presentation:  
 The role of Myelin Oligodendrocyte Glycoprotein (MOG) as putative auto-Ag in central 
nervous system AID (Chapter 2); 
 Investigation of the involvement of aberrant PTM in the ethiopathogenesis of Primary 
Biliary Cirrhosis (Chapter 3).
  
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 2: MYELIN 
OLIGODENDROCYTE 
GLYCOPROTEIN 
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STRUCTURE AND FUNCTION OF 
MYELIN OLIGODENDROCYTE 
GLYCOPROTEIN 
Myelin Oligodendrocyte Glycoprotein (MOG) is a 218 Aa (28 kiloDalton, kDa) member of the 
immunoglobulin (Ig) superfamily exclusively expressed in the central nervous system (CNS). In 
particular, it is a minor component of myelin (0,05%), and its localization is on the outermost 
surface of myelin sheath and the plasma membrane of oligodendrocytes41 (Figure 11). The specific 
function of the protein still has to be clarified: it was shown that it is an important surface marker 
of oligodendrocyte maturation, and it was suggested that it might act as cell adhesion molecule, 
regulator of microtubule stability and mediator of interactions between myelin and immune 
system42. The MOG gene maps to the region encoding the MHC in both humans and rodents, and 
the protein is highly conserved between species43. 
 
Figure 11: Proteins of the myelin sheath, oligodendrocytes and neurons.  
MAG, Myelin-Associated Glycoprotein; MBP, Myelin Basic Protein; PLP, Proteo-Lipid Protein44. 
 
In 1996, Kroepfl et al. proposed a pattern of MOG topology (Figure 12)45, hypothesizing that the 
protein contains the following domains:  
 an extracellular domain (MOGED) that comprises an Ig-like portion and the N-linked 
carbohydrate moiety (N-terminal); 
 a first typical transmembrane domain; 
 a second hydrophobic domain, which is probably associated with the membrane but not 
spanning it. In this region there are two Cys that appear to be targets for palmitoylation; 
 a small intracellular domain (C-terminal). 
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Figure 12: Proposed model for MOG membrane topology42. 
 
Crystal structure of rMOGED46 and mMOGED47 were resolved with X-ray crystallography in 2003 
(Figure 13). These studies proved that the overall structure of MOGED adopts a topology of an Ig-V 
domain structure, which consists of a compact -sandwich domain with one antiparallel -sheet 
(strands A, B, E, and D) packing against a mixed -sheet (strands A, G, F, C, C, and C). The N and 
C termini are at opposite ends of the molecule. In addition to the -strands, there are four 310 helices 
at the periphery of the molecule. The core packing residues of MOGED is represented by a canonical 
disulfide bond (Cys24–Cys98) that packs against the consensus residue (Trp39), and a salt bridge 
between Arg68 and Asp92. The glycosylation site of MOG (Asn31) is located in the BC loop, exposed 
at the top, membrane-distal side of MOGED. 
 
 
Figure 13: X-ray crystal structure of rMOGED (on the left) and mMOGED (on the right). 
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MOGED was crystallized as a monomer, but the observed interactions within the crystalline lattice 
were suggestive of a biologically relevant MOGED dimer. Indeed, there are three regions of crystal 
contacts observed within the lattice of MOG, and only one of these was observed to lie on a 
crystallographic twofold, forming an antiparallel, head-to-tail dimer within the lattice. The shape 
complementarity index at the dimer interface is high, representing a value that is comparable to 
that observed in Ab–Ag interactions. The dimer interface runs along the long axis of the molecule, 
with interactions predominantly involving the extreme N terminus, the A-A’ loop (residues 8–11), 
the C–C’ loop (residues 40–46), and the F–G strand -hairpin (residues 95–112) (Figure 14). The 
interface is dominated by van der Waals interactions and hydrogen bonds, and all the residues 
mediating the dimeric contacts are conserved among species.  
These findings confirmed that native MOG exist as a mixture of monomeric and dimeric species, as 
repeatedly reported 42,48,49. It was demonstrated that the monoclonal Ab (mAb) 8-18C5, which is 
able to mediate demyelination in vitro and in vivo, and to augment clinical EAE in rats50, is capable 
to recognize proteins with relative mass of 26–28 kDa (monomeric MOG) and 54 kDa (dimeric 
MOG) in CNS myelin from mouse and human brain as well as native hMOG purified from brain. It 
was also confirmed that the observed dimer was not merely due to crystal packing artifacts using 
several biochemical techniques (e.g. native gel electrophoresis). 
 
 
Figure 14: Schematic representation of the MOGED head-to-tail dimer  
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THE CONTROVERSIAL ROLE OF 
MOG IN AUTOIMMUNITY 
Central nervous system autoimmune diseases in which MOG is 
putatively involved 
Multiple Sclerosis (MS) 
MS is the major inflammatory demyelinating disease of CNS51. The disorder represents a prime 
cause of neurological disability in young adults52, resulting in wide health, psychological, and socio-
economic consequences. MS is marked by inflammatory infiltrates, both axonal and neuronal 
damage, destruction of myelin sheath and oligodendrocytes, and glial proliferation, leading to the 
formation of large confluent plaques of demyelination in white and grey matter51. While most of 
the immune mechanisms associated with demyelination and tissue damage in MS are present in 
other CNS pathologies, it has to be stressed that widespread demyelination with preservation of 
axons is highly specific for MS, with the exception of viral infection of oligodendrocytes53 or the 
presence of toxins affecting myelin or oligodendrocytes54. 
The course of this chronic pathology usually starts with a clinically isolated syndrome (CIS) that 
evolves in clinically definite MS in 63% of cases55. The majority of MS pts (85-90%) develop 
relapsing-remitting MS (RRMS), in which worsening of clinical symptoms alternate with periods 
of remission51,56. About 40% of RRMS pts develop secondary progressive MS (SPMS), a form 
characterized by a progression of the disease associated with decrease or absence of relapses. In 10-
20% of pts, MS manifests with a slow and progressive exacerbation of symptoms without remission 
(primary progressive MS, PPMS)56 (Figure 15).  
 
Figure 15: Time course of the different MS subgroups. 
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As immune mechanisms are at the core of the disease, MS is widely regarded as autoimmune. 
However, MS triggering events still have to be clarified, as both genetic and environmental factors 
are involved57. The extremely heterogeneous pattern of symptoms and disease course makes 
challenging to both diagnose and predict the pathology progression58.  
In the last decades, much efforts were made to characterize the auto-Ab response in MS59,60, as the 
presence of oligoclonal Ig bands in the CSF of most MS pts uncovered the potential involvement of 
an autoimmune humoral reaction in MS pathogenesis61. Auto-Ab may have different biological 
functions in MS, ranging from a mere bystander phenomenon to primary involvement at different 
stages of the immunopathogenic 
cascade (e.g. demyelination), 
facilitation of repair mechanisms (e.g. 
remyelination) and balancing of the 
natural autoimmunity system. 
Therefore, a precise characterization of 
the auto-Ab response in MS may enable 
the identification of BM for diagnosis, 
clinical classification, monitoring of 
disease activity and follow-up 
prediction (Figure 16)62.  
Myelin Ag were longtime considered as 
the primary targets of humoral 
autoimmune response in MS, and 
recently the focus was shifted to the 
entire CNS cells58, but unfortunately 
the Ag involved in the disorder have not 
been clearly identified yet.  
 
Figure 16: Potential use of Ab as BM in MS. 
 
Experimental Autoimmune Encephalomyelitis (EAE) 
As the access to MS tissue and biological fluids samples is often restricted, and the modification of 
experimental conditions is limited in human studies, it is necessary to employ animal models to 
understand the immunopathological mechanisms of the disease. Due to the extreme complexity of 
MS, a single animal model is not representative of all the clinical features of the disease53. Large 
part of the MS pathophysiology was uncovered using EAE, which is the most extensively used MS 
model. Initially, EAE induction was performed using brain or spinal cord homogenates, or purified 
myelin proteins, added with an adjuvant. To date, the model is obtained immunizing the animals 
with an emulsion of adjuvant and recombinant or synthetic myelin proteins (or peptides deriving 
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from them) by subcutaneous injection. The disease can be achieved also by cell transfer from EAE 
donors to naïve recipient53, whereas spontaneous disease can be obtained in transgenic mice63.  
Concerning MS, EAE closely parallels key features of the human disease, as inflammation, 
demyelination and gliosis64. Nevertheless, EAE differs from MS in several remarkable aspects. 
First, EAE requires an external immunization step to develop65, typically with adjuvant containing 
bacterial components highly capable of activating the innate immune system66. Second, EAE 
represents the prototype T cell-mediated model, whereby CD4+ T cells are the major effector of the 
disease, while MS immunopathology is characterized by both humoral and cellular mechanisms51. 
Third, in EAE the inducing Ag are known, while the triggering event of MS is still matter of debate. 
It is evident that usage of different immunizing agents, protocols, or animals (mice, rats, primates, 
etc.) will lead to a different subtype of immune response, and therefore to a particular CNS 
inflammatory disorder. Therefore, the use of one of the EAE model variation should be guided by 
a rational selection based on a specific research question. 
 
Neuromyelitis Optica (NMO) 
NMO is a severe inflammatory demyelinating disease characterized by severe attacks of neuritis 
and myelitis. The pathology affects selectively optic nerves and spinal cord (but not necessarily with 
co-occurrence), typically spares the brain in the early stages, and generally follows a relapsing 
course67,68. Until recently, NMO was considered an MS variant, as both are featured by optic 
neuritis, myelitis and inflammatory demyelination69,70, but currently it is known that the disorders 
have distinct clinical, neuroimaging and laboratory features67,71 (summarized in Table 2).  
 
Table 2: Definitions and characteristics of MS and NMO75 
 
The real breakthrough in NMO field was achieved in 2004 by Lennon et al., with the discovery of 
NMO-IgG, an auto-Ab to aquaporin-4 (AQP4) present in more than 70% NMO pts72. NMO-IgG 
recognizes aquaporin-4 (AQP4), the main channel responsible for water homeostasis regulation in 
the CNS. AQP4 is located in astrocyte membranes, and the areas where its expression is normally 
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higher coincide with the sites of brain lesions in 10% of pts73,74. The identification of a specific 
serological disease BM enabled to simplify the diagnosis and to investigate the molecular immune-
mechanisms. Nevertheless, the role of NMO-IgG and AQP4 has yet to be clarified. Despite the 
NMO-IgG identification as disease BM, a small percentage of pts remains seronegative. In this 
context, the presence and significance of anti-MOG auto-Ab in NMO is matter of debate. 
 
Role of MOG in central nervous system autoimmunity: first 
hypothesis and animal models contribution 
Inflammatory demyelinating diseases of CNS include numerous and heterogeneous pathologies, 
such as MS and NMO. The evidence of an Ab-dependent mechanism contributing to at least a 
subset of pts affected by these disorders is highlighted by both histopathological investigations and 
clinical response to plasma exchange76. First studies aimed at understanding the mechanism(s) that 
induces demyelination dates back to the period between ‘800 and the early ‘900. In 1906, Marbourg 
proposed the existence of a soluble myelinolytic factor, while Babinski hypothesized that myelin 
was attacked by inflammatory cells77. By the use of EAE animal model, today it is well known that 
both mechanisms are possible, and that selective primary demyelination can be induced either by 
cytotoxic T-cells recognizing an oligodendrocyte Ag78,79, or by specific demyelinating auto-Ab80. 
The advent of myelinating tissue culture models in the 60s allowed to discover that sera and 
cerebrospinal fluid (CSF) from MS pts contain a soluble factor able to induce demyelination in 
vitro81,82. This phenomenon was observed predominantly in pts with active disease83, but rarely in 
control sera82,83. A similar demyelinating factor was found in the sera of EAE animals after 
sensitization with CNS homogenate81,84–87. Later, it was discovered that this soluble factor was an 
Ig able to induce demyelination through complement activation both in vitro88 and in vivo89,90. The 
target Ag of demyelinating Ab was identified as MOG91 using the mouse mAb 8-18C5 directed 
against rat cerebellar glycoproteins49. Since then, MOG became the most extensively studied 
putative Ag in CNS AID. The encephalitogenic properties of MOG are believed to result from the 
extracellular localization of its IgV-like domain on the outermost myelin lamellae, which makes it 
an exposed target accessible to autoimmune attack even on intact myelinated axons92,93.  
The attention in MOG was further encouraged by the demonstration of the association between 
demyelinating activity of guinea pig EAE serum and anti-MOG Ab titers91. The presence of 
demyelinating Ab anti-MOG was then confirmed in both rodent and primates EAE models50,80,94, 
and it was shown that anti-MOG Ab are capable to induce widespread plaque-like demyelination 
in the white matter95 and in the cerebral cortex96 in vivo. In MOG-induced EAE models, the subpial 
demyelinating cortical lesions were identical to those present in MS pts96, while these lesions are 
absent in Ab-independent EAE models97. 
In 2004, von Büdingen et al.98 demonstrated, using an EAE marmoset model, that only auto-Ab 
directed against conformational epitopes of MOG are responsible for demyelination worsening. 
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Indeed, they observed the occurrence of IgG deposition and complement activation only in 
association with the presence of conformational auto-Ab. In the same publication, they reported 
that conformational auto-Ab are also an essential factor for disease dissemination within CNS, a 
typical hallmark of human MS. A year later, Marta et al.99 obtained an EAE model immunizing 
C57BL/6 mice with either rat (rMOG) or hMOG. Although anti-MOG Ab were generated in both 
cases, only immunization with hMOG led to a B-cells dependent disorder. In particular, they 
showed that the mutation of Pro at position 42 with Ser in hMOG (as in rMOG) results in a change 
in the mechanism of encephalitogenicity from B-cell dependent to independent, reflecting the close 
connection between Ag conformation and Ab pathogenicity. They established also that only Ab 
from mice immunized with unmodified hMOG were encephalitogenic in primed B cell-deficient 
mice. Furthermore, they demonstrated the capability of encephalitogenic anti-hMOG Ab to bind 
properly glycosylated MOG. Based on these data, they hypothesized that non-pathogenic Ab bind 
linear MOG determinants, while pathogenic Ab recognize only conformational, glycosylation-
dependent epitopes.  
Understanding the three-dimensional structure of MOGED allowed the identification of solvent-
exposed surfaces that may be involved in Ab-mediated demyelination. As previously mentioned, 
Ab demyelinating activity is strictly dependent on 
epitope conformation, with the exception of a 
minor subset of murine mAb able to bind also 
peptides containing the 63-87 region. This 
sequence includes the DE loop, which forms part of 
a protruding surface at the top of BED sheet and 
comprises highly exposed residues100. Additionally, 
it was shown that Lewis rats immunized with 
MOG(35-55) develop a demyelinating variant of 
EAE, leading to the hypothesis that also this 
fragment encompasses a B-epitope101. This 
assumption is supported by MOG(35-55) 
localization into the surface-exposed and highly 
flexible CC’ loop (Aa residues 41-46). Furthermore, 
MOGED was crystallized in complex with a chimeric 
fragment Ag-binding (Fab) derived from 8-18C5 
(Figure 17)46.  
 
Figure 17: Overall structure of Fab-MOGED complex.  
The binding site of Fab is shown with surface representation,  
and atoms contacting MOGED are colored in red. 
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The capacity of 8-18C5 to detect MOG from different species and to inhibit the binding MOG-
specific mAb to the protein indicate that 8-18C5 recognizes a central conserved epitope. The crystal 
structure of MOG-Fab complex disclosed that 8-18C5 binds the upper, membrane-distal surface of 
MOGED, namely the N terminus and the BC, C’C’’ and FG loops. The major interaction site is formed 
by the three complementarity determining regions (CDR) of the mAb heavy chain and both residues 
in the G strand and in the FG loop (Aa residues 101-108), which represent 65% of the total MOGED 
interaction surface. The highly specific interaction with the 101-108 region is also supported by 
presence of van der Waals bonds between MOG residues and Fab in the periphery of the binding 
site.  
The discovery of the crucial relevance of MOG conformation and glycosylation in the occurrence of 
EAE pathogenesis represents a concrete breakthrough in the CNS autoimmunity field. 
 
MOG as putative auto-Ag in human CNS AID: an issue open to 
discussion 
Despite the interesting and grounded results achieved in animal models, the demonstration of anti-
MOG Ab pathogenicity in humans is still lacking. The main reason for the inhomogeneous and 
controversial data on the role of MOG in MS autoimmune response is the use of different assays 
testing different MOG preparations (summarized in Table 3). Namely, the causes of this debatable 
circumstance concern: 
1. sequence, conformation and origin of MOG used as Ag; 
2. technique used to measure anti-MOG Ab; 
3. Ig isotype detected; 
4. absence of standardized MS subtype definition; 
5. nature of negative controls (normal blood donors, NBD; other neurological disease, OND; 
etc.). 
Some of these aspects were summarized in the following table: 
  
Type of MOG recombinant MOG (different portions) expressed: 
- in mammalian cells 
- in E.coli 
- by in vitro translation 
synthetic peptides (1 to 125 Aa) 
purified from human myelin 
tetramer 
cell-based assays (human or murine cells expressing hMOG on their surface) 
MOG 
sequence 
human, rat, mouse 
Ig isotype IgG, IgM, IgA 
Immunossay ELISA, Immunoblot, Fluid Phase, Elispot, Fluorescence-activated flow cytometry 
(FACS) 
 
Table 3: MOG preparations and immunoassays used for anti-MOG Ab detection102 
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Since 1991, the role of anti-MOG Ab in MS and in other CNS AID was extensively investigated 
(results are reviewed in Table 4 62,103,104). The first studies were carried out employing hMOG 
purified from brain white matter as Ag in ELISA testing MS pts sera and CSF. This methodology 
enabled the detection of anti-MOG Ab in the CSF of a subset of MS pts, but also in the control 
cohort105. Afterwards, comparable results were obtained using not-refolded hMOG extracellular 
domain expressed in E.coli106. The use of full-length glycosylated mouse MOG (mMOG) expressed 
in mammalian cells allowed the identification of high IgM titers in MS pts during the first 
demyelinating event, and elevated IgG during relapses and secondary chronic progressive MS. The 
results obtained with MS subgroups were compared with NBD and remission pts107. These findings 
permitted to hypothesize the importance of epitope glycosylation and conformation also in human 
MS. Later studies confirmed the theory of a pathogenic role of anti-MOG Ab108–113, while others 
denied it114–118. Additionally, in the recent years the focus partially shifted to pediatric MS119–122 and 
other neurological AID (e.g. NMO and acute disseminated encephalomyelitis, ADEM), leading to 
an even more intricate situation. 
In this context, our research group focused on the detection of serum IgG and IgM directed against 
the extracellular domain of MOG, with an emphasis on the protein conformation. To do this, Gori 
et al.118 developed a method to produce recombinant rMOG1-125(His)6 centered on the on-column 
refolding and affinity purification of the protein produced in E.coli. MOG folding was verified by 
circular dichroism spectroscopy, then the protein was used as antigenic probe in SP-ELISA. Results 
obtained disclosed that rMOG1-125(His)6 is not able to detect serum Ab neither in MS pts nor in 
controls using an immunoenzymatic solid-phase assay. 
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Study Method Ag Ig isotype Sample 
tested 
Results & Discussion 
Xiao 1991105 ELISA hMOG from 
white matter 
IgG Plasma 
and CSF 
Anti-MOG IgG were detected in 
7/30 MS pts (compared with 
controls). No anti-MOG IgG Ab 
were demonstrable in plasma. 
Karni 
1999123 
ELISA hMOG 
expressed in 
E.coli 
IgG Plasma 
and CSF 
Anti-MOG Ab are elevated in 
MS, but also in other neurologic 
diseases. 
Lindert 
1999124 
 
 
WB hMOG 
expressed in 
E.coli 
IgG Serum The frequency of anti-MOG 
seropositive samples was 
significantly higher in MS than 
in normal random controls 
(positivity percentages: MS 
54%; controls 22%). 
Reindl 
1999106 
WB 
ELISA 
hMOG 
expressed in 
E.coli 
IgG Serum 38% of MS are seropositive for 
anti-MOG IgG (persistent 
response). Similar % were found 
in OND, but the response is 
transient. 
Egg 2001125 Immunoblot hMOG 
expressed in 
E.coli 
IgG, IgM, 
IgA 
Serum 72% of MS have anti-MOG Ab, 
and the dominating one is anti-
MOG IgM. A significant 
relationship between anti-MOG 
IgA and a progressive disease 
course was found. 
Berger 
2003126 
WB hMOG 
expressed in 
E.coli 
- Serum of 
CIS 
patients 
Analysis of anti-MOG (and 
MBP) Ab enables to predict 
early conversion to clinically 
definite MS. 
Vojdani 
2003127 
ELISA Syntethic 
MOG 
peptides 
IgG, IgM, 
IgA 
Serum Detection of anti-MOG peptides 
Ab, together with the 
measurement of other 
serological parameters, could be 
used for the confirmation of MS 
diagnosis. 
Kennel de 
March 
2003128 
ELISA, ELISPOT Synthetic 
MOG(35-55), 
recombinant 
MOG 
IgG, IgM, 
IgA 
Serum MS patients had significantly 
higher levels of anti-MOG IgA 
and MOG-specific spot-forming 
cells than controls. 
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Study Method Ag Ig isotype Sample 
tested 
Results & Discussion 
Gaertner 
2004107 
ELISA mMOG 
transfected 
AG8 cells 
IgG, IgM Serum Anti-MOG IgM were elevated 
during the first demyelinating 
event, while higher MOG-
specific IgG were found during 
relapses and in secondary 
chronic progressive MS 
compared to pts in remission 
and controls. 
Lampasona 
2004129 
Liquid-phase 
radiobinding 
assay 
hMOG in 
vitro 
translated 
IgG, IgM Serum The frequency of positive 
samples with low titers of anti-
MOG IgG (≤5.7%) and IgM 
(≤8.3%) was similar in both MS 
and control, disclosing that anti-
MOG Ab are not disease specific. 
Mantegazza 
2004130 
ELISA hMOG 
expressed in 
E.coli 
IgG Serum 
and CSF 
Serum anti-MOG Ab were 
detectable in 13.7% of MS pts, 
mainly in SPMS (25%), in 13.7% 
of OND pts and in 6.2% of 
controls. A direct correlation 
between disease severity and 
anti-MOG titer was found only 
in PPMS and SPMS pts. Anti-
MOG Ab were present in the 
CSF of 11.4% MS patients and 
18.9% OND pts.  
Zhou 
2006109 
Cell-based assay hMOG 
transfected 
LN18 cells 
IgG, IgM Serum IgG but not IgM Ab-titers to 
native MOG were significantly 
higher in MS compared with 
different control group (highest 
prevalence in PPMS). The 
presence of a pathogenic Ab 
response to native MOG in a 
subgroup of MS patients was 
suggested. 
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Study Method Ag Ig isotype Sample 
tested 
Results & Discussion 
Lalive 
2006110 
Cell-based assay hMOG 
transfected 
CHO cells 
IgG Serum Compared with healthy 
controls, native MOG-specific 
IgGs were most frequently 
found in serum of CIS and 
RRMS, only marginally in 
secondary progressive SPMS 
PPMS. Therefore, cell-based 
assay provides a practical 
serologic marker for early 
detection of CNS autoimmune 
demyelination. 
ELISA (only on 
CIS cohort) 
hMOG 
expressed in 
E.coli 
IgG 
Kuhle 
2007114 
WB hMOG 
expressed in 
E.coli 
IgG, IgM Serum of 
CIS 
patients 
No associations were found 
between the presence of anti-
MOG Ab and progression to MS. 
Pelayo 
2007115 
WB hMOG 
expressed in 
E.coli 
ND Serum of 
CIS 
patients 
No associations were found 
between the presence of anti-
MOG Ab and CIS-to-MS 
conversion. 
O’connor 
2007116 
ELISA (DELFIA) hMOG 
expressed in 
E.coli 
(refolded) 
IgG, IgM Serum 
and CSF 
It was shown that tetramer RIA 
is the most sensitive 
methodology for MOG auto-Ab. 
MOG-specific auto-Ab were 
identified in a subset of ADEM 
but only rarely in adult-onset 
MS cases, indicating that MOG 
is a more prominent target 
antigen in ADEM than MS. 
Solution phase 
radioimmuno-
assay (RIA) 
hMOG in 
vitro 
translated 
(self-
assembling 
radiolabeled 
tetramers) 
Menge 
2007111 
ELISA 
LiPhELIA 
hMOG 
expressed in 
E.coli 
IgG Serum SP methods are superior in 
measuring anti-MOG Ab, but do 
not have the discriminative 
power to isolate only the 
disease-relevant ones. Indeed, 
anti-MOG IgG reactivity of MS 
and controls are comparable. 
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Study Method Ag Ig isotype Sample 
tested 
Results & Discussion 
Wang 
2008131 
ELISA hMOG 
expressed in 
E.coli 
IgG, IgM Serum The presence of anti-MOG IgG 
was related with an increase in 
risk of developing MS. This 
association may in part reflect 
cross-reactivity between MOG 
and Epstein-Barr nuclear 
antigen. 
Klawiter 
2010113 
ELISA hMOG 
produced 
using 
baculovirus 
and insect 
cell-mediated 
expression 
system 
IgG Serum 
and CSF 
Serum and CSF anti-MOG Ab, 
together with albumin levels, 
were used to calculate s a marker 
of intrathecal MOG Ab 
production, the rMOG index, 
which was found to be elevated 
in MS compared to controls. 
Results obtained display that 
intrathecal anti-MOG Ab 
production may be more 
pronounced in progressive than 
relapsing forms of MS.  
Gori 2011118 ELISA Refolded 
rMOG 
expressed in 
E.coli 
IgG, IgM Serum Anti-MOG Ab are not detectable 
in both MS and controls. 
Menge 
2011132 
ELISA 
Denaturing 
ELISA 
Recombinant 
refolded 
hMOG1-125, 
hMOG1-118 
and rMOG1-
125 produced 
in E.coli 
IgG Serum High-titer of anti-MOG Ab were 
identified in ≈8% of tested 
samples, and are highly specific 
for certain epitopes of hMOG. In 
RRMS, high-titer anti-MOG IgG 
correlate with disability. 
 
Table 4: Summary of the most relevant studies on anti-MOG Ab response in MS. 
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AIM OF THE WORK 
MOG is one of the most studied Ag candidate in the case of demyelinating AID, especially in 
MS102,104. The hypothesis of MOG involvement in the autoimmune reaction is due to the exposition 
of its Ig-like extracellular domain on the outermost surface of myelin sheaths, allowing the access 
of potential auto-Ab to the protein41. Despite the presence of numerous studies based on MOG, the 
role of the protein in CNS AID is still controversial. Indeed, the use of inhomogeneous protein 
preparations and different immunological protocols to reveal anti-MOG Ab led to the presence of 
contrasting and debatable data. In this context, we decided to study the involvement of MOG in 
different CNS AID using the refolded recombinant rat extracellular domain of the protein, rMOG1-
117. The choice of a shortened protein fragment compared with the so-called standard extracellular 
domain MOG1-125 was inspired by an attempt to avoid the solubility issues characterizing rMOG1-
125. Indeed, rMOG1-125 sequence comprises also a small transmembrane portion, which is highly 
hydrophobic (F119YWI122). The removal of these Aa residues may lead a more soluble recombinant 
product, which is more appropriate to be employed as Ag in immunological solid-phase assays. The 
initial decision of our research group to work with rMOG as antigenic probe dates back to the early 
2000, and was guided by the fact that the protein was used in studies with animal model, aimed to 
understand the molecular mechanisms of MS. Furthermore, one of our primary focus was to restore 
the native protein conformation through the refolding procedure, in order to preserve MOG 
conformational epitopes. This feature supported the employment of rat protein because the 
reference conformational studies were carried out on the rat isoform46 (together with the mice 
one47). However, the use of the rat protein in studies on human pathology may lead to confusing 
data: hMOG and rMOG share a >90% homology, but rMOG has a Ser in position 42, while hMOG 
has a Pro (Figure 18). As already speculated by Marta et al.99, this single Aa difference could lead 
to structural differences, with consequent alteration of the immunogenicity of the probe.  
 
Figure 18: rMOG1-117 – hMOG1-117 BLAST alignment.  
In red, Aa differences. + indicates a conservative mutation. 
Ser42 and Pro42 are highlighted in yellow. 
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Based on the foregoing, recombinant rMOG1-117  was used as antigenic probe in SP-ELISA aimed to 
disclose different aspects of MOG immunogenicity in several pathologies. In particular, we 
evaluated the role of MOG in: 
 EAE mice model of MS; 
 NMO; 
 NMO-like EAE rat models. 
Furthermore, as the Ag production step is crucial in the BM research field, part of the work was 
focused on MOG production through molecular biology techniques. In particular, we worked on: 
 Optimization of rMOG1-117 productive process; 
 Semi-synthesis of aberrantly N-glucosylated hMOG1-117. 
The previously mentioned aspects will be treated separately in this presentation. Specifically, the 
work is structured as follows: 
 Part I: Immunological role of MOG in the EAE mice model of MS 
The EAE mice model was obtained by Dr. Rina Aharoni (Weizmann Institute, Rehovot, Israel) 
immunizing C57BL/6 mice with commercial mMOG(35-55) peptide. We tested sera samples of 
mice with various clinical course (active disease with different disease score; spontaneous 
recovery; immunized mice that have not developed any clinical sign), comparing them with 
naïve mice. We tested three temporally distinct cohorts of sera, to assess different hypothesis: 
1. First cohort: preliminary SP-ELISA screening on rMOG1-117(His)6, CSF114 and 
CSF114(Glc).  
17 EAE active disease, 1 spontaneous recovery and 8 naïve mice sera samples were 
tested in SP-ELISA to assess the presence of Ab response against MOG. The N-
glucosylated peptide CSF114(Glc) was also tested, together with its un-glucosylated 
analog, to assess the role of N-glucosylation in the mice model. 
2. Second cohort: anti-rMOG1-117(His)6 IgM screening. 
16 EAE active disease, 3 spontaneous recovery, 6 immunized mice that that have not 
developed any clinical sign (“no disease”) and 12 naïve mice sera samples were tested 
in SP-ELISA to verify the hypothesis of a protective role of anti-MOG IgM. 
3. Third cohort: rMOG1-117 epitope mapping. 
33 EAE active disease, 12 spontaneous recovery, 2 “no disease” and 9 naïve mice sera 
samples were tested to determinate the presence of an epitope spreading mechanism 
against MOG portions different from the immunizing peptide mMOG(35-55). For this 
purpose, the MOG(1-117) sequence was divided in 6 peptide fragments (1-34, 35-55, 56-
75, 76-95 and 96-117), which were subsequently used as antigenic probe in SP-ELISA. 
Results obtained were compared with the one achieved on the full-length recombinant 
protein. 
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 Part II: Evaluation of MOG-IgG and CSF114(Glc)-IgG as additional BM in NMO 
NMO is an inflammatory demyelinating disorder of CNS that affects spinal cord and optic 
nerve. In 2004, Lennon et al. discovered a specific disease BM, NMO-IgG, that is an auto-Ab 
of the IgG class directed against AQP472. As NMO-IgG is present in approximately 70% of NMO 
pts, the evaluation of other NMO BM may be useful to perform a more accurate diagnosis. 
Recently, the role of MOG as auto-Ag in NMO was extensively studied, but the relevance of 
anti-MOG Ab in this pathology still needs clarifications. These findings disclosed the potential 
of anti-MOG IgG as additional NMO BM, but to date the involvement of MOG in NMO is still 
matter of debate. In this context, we assessed the presence of a specific IgG reactivity against 
MOG testing 21 NMO pts sera in SP-ELISA. As NMO is an MS-related disorder, we tested the 
same sera on CSF114(Glc), and results obtained for both Ag were compared with a cohort of 20 
NBD using a cutoff calculated as (mean value of NBD)+3*(standard deviation of NBD). 
 
 Part III: Immunological role of MOG in NMO-like EAE rat models 
Several attempts to obtain a specific Rattus Norvegicus NMO-like model were made by Prof. 
Jerome De Seze group (Hôpitaux universitaires de Strasbourg, France) immunizing Brown 
Norway rats with recombinant, not-refolded rMOG1-117(His)6 produced in our lab. In particular, 
it was studied the possibility to reproduce the disorder administering two doses of immunizing 
agent, or using an IgG passive-transfer strategy. In this context, we evaluated the Ab response 
elicited in the NMO-like model to disclose the correlation between anti-MOG Ab titer and 
disease progression. A first attempt to evaluate the model obtained immunizing Brown Norway 
rats with rMOG1-117(His)6 was made studying the time-course of IgM and IgG anti-MOG Ab 
response. Subsequently, it was assessed the correlation between Ab titer against refolded MOG 
and both time- and disease-course in four different immunization protocols. The same animal 
cohort was examined to verify the presence of a response against unfolded MOG and 
CSF114(Glc). 
 
 Part IV: Optimization of rMOG1-117 production process 
Ag production process is a key step of the BM research in both diagnostic and prognostic fields. 
As mentioned several times during this presentation, MOG is the most studied candidate Ag in 
the case of CNS AID, and therefore the production of this protein as antigenic probe is of crucial 
relevance to study the immunopathogenesis of disorders such as MS or NMO. In our lab, we 
decided to employ recombinant rMOG1-117, which was obtained through the expression and 
purification protocol published by Gori et al.118. This methodology includes numerous laborious 
and time-consuming phases that invalidate productivity. Therefore, the aim of this project was 
to improve rMOG1-117 production process, focusing on the optimization of both expression in 
E.coli and purification/on-column refolding of the protein.  
Myelin Oligodendrocyte Glycoprotein 
 
35 
 Part V: Semi-synthesis of aberrantly N-glucosylated hMOG1-117 
The involvement of aberrant PTM on MOG in triggering CNS autoimmunity is a crucial topic. 
In this context, we hypothesized that an aberrant N-glucosylation on the MOG native site of 
glycosylation (Asn31) may be involved in the immunopathogenesis of CNS demyelinating 
disorders. This assumption is supported by the presence of a preliminary study proving that 
[Asn31(Glc)]hMOG(30-50) is capable to recognize auto-Ab in MS pts sera, while the 
corresponding un-glycosylated hMOG(30-50) is inactive34. Furthermore, it is well documented 
that the N-glucosylated type I’ -turn peptide CSF114(Glc) is able to detect specific and high 
affinity Ab in MS patients, disclosing the relevance of N-glucosylation in MS autoimmunity36,37. 
Therefore, we decided to develop a NCL semi-synthetic strategy to produce [Asn31(Glc)]hMOG1-
117, which will be compared with both un-glucosylated hMOG1-117 and CSF114(Glc) from an 
immunological point of view. The chosen protocol provides the formation of an amide bond 
between a recombinant protein bearing an N-terminal Cys and a peptide with a C-terminal 
thioester. For this purpose, it was decided to produce the hMOG fragment (35-117) using 
molecular biology tools, engineering the sequence to obtain the N-terminal free Cys. 
Specifically, a selective point mutation was introduced at the 35 residue (M35C) and the 
sequence was extended at the N-terminus with the TEV-protease consensus sequence. The C-
terminal active ester of the peptide fragment [Asn31(Glc)]hMOG(1-34) was prepared at the 
SOSCO Laboratory (Universitè de Cergy Pontoise, France). 
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PART I: IMMUNOLOGICAL ROLE OF 
MOG IN THE EAE MICE MODEL OF 
MS 
As stated in the previous section, the aim of this study concerns the evaluation of the immunological 
role of MOG in an EAE mice model of MS obtained immunizing C57BL/6 mice with a commercial 
mMOG(35-55) peptide. We tested sera samples of mice with various clinical courses (active disease 
with different disease score; spontaneous recovery; immunized mice that have not developed any 
clinical sign), comparing them with naïve mice. In particular, we assessed different hypothesis 
testing three temporally distinct cohorts of sera: 
1. First cohort: preliminary SP-ELISA screening on rMOG1-117(His)6, CSF114 and CSF114(Glc): 
we evaluated the presence of Ab response against MOG, together with the role of N-
glucosylation in the MS mice model. 
2. Second cohort: anti-rMOG1-117(His)6 IgM screening: we investigated a putative protective 
role of anti-MOG IgM. 
3. Third cohort: rMOG1-117 epitope mapping: we explored the possible presence of Ab directed 
against MOG epitopes different from the immunizing peptide mMOG(35-55), i.e. a 
phenomenon known as epitope spreading. MOG(1-117) sequence was divided in 6 peptide 
fragments (1-34, 35-55, 56-75, 76-95 and 96-117), which were subsequently used as 
antigenic probe in SP-ELISA. Results obtained were compared with the one achieved on 
full-length recombinant protein. 
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Results & Discussion 
First cohort: preliminary SP-ELISA screening on rMOG1-117(His)6, 
CSF114 and CSF114(Glc) 
Results are summarized in Figure 19. No response to peptide Ag was detected in EAE mice 
compared with naïve. In the case of IgG, EAE mice showed high response to rMOG1-117(His)6, while 
only the recovery mice displayed a high and consistent response to rMOG1-117(His)6 compared with 
both EAE and naïve mice. The latter finding allowed us to hypothesize a protective role for anti-
MOG IgM. 
 
 
 
Figure 19: Data distribution for IgG (top) and IgM (bottom) in EAE (left) and naïve mice (right). 
Recovery mice is highlighted with a red circle. 
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Second cohort: anti-rMOG1-117(His)6 IgM screening 
Results obtained are shown in Figure 20. Cutoff value was calculated as (mean of naïve)+ 
3*(standard deviation of naïve). Tests on the new cohort displayed that most of recovery and “no 
disease” mice have anti-MOG IgM titers, confirming the hypothesized anti-MOG IgM protective 
role. However, anti-MOG IgM are present also in the active disease group.  
A limitation of these data concerns the small recovery and “no disease” cohorts. Therefore, the 
obtained results have to be considered as preliminary. The small size of the cohort and the difficulty 
in the model management (most of the mice do not survive beyond day 22) prevented us to perform 
a time-course and a disease-course analysis of the Ab response against rMOG. 
 
Figure 20: Data distribution of IgM against rMOG1-117(His)6 tested the second cohort.  
Cutoff value is shown with the dotted line. 
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Third cohort: rMOG1-117 epitope mapping 
Results obtained are shown in Figure 21. No significant response was detected against any Ag in 
the case of IgM comparing EAE with naïve mice. On the contrary, EAE active disease mice displayed 
high and specific IgG response against mMOG(35-55) and recombinant rMOG1-117, while no 
response was detected against the other Ag. The higher response against the recombinant full-
length protein compared with the immunizing peptide allowed us to speculate the presence of a 
MOG conformational epitope recognized by auto-Ab. Indeed, the recombinant protein is able to 
reproduce both Aa sequence and conformation of the native Ag, which is probably stable during 
the coating phase. The peptide probe instead is able to mimic only a linear, short portion of the 
protein, and due to its flexibility may display a random conformation on the plate. Therefore, it can 
be hypothesized the presence of two distinct families of auto-Ab: one directed against a linear 
peptide reproduced by both mMOG(35-55) and the recombinant protein, and one able to detect 
conformational epitope(s) on rMOG1-117. To verify this assumption, it will be necessary to test both 
Ag in a competitive ELISA test. 
 
 
Figure 21: Data distribution for IgG (top) and IgM (bottom) in EAE (left) and naïve mice (right). 
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The possibility to investigate MS using an animal model is remarkably advantageous, as it enables 
to study in depth the disorder from a clinical point of view, and also to have a large number of 
biological samples. Conversely, both development and management of a proper disease model is 
complicated. For example, the use of the EAE mice model of MS allows to examine 
immunopathological and molecular aspect characterizing the acute phase of the disorder, because 
the animals did not survive long after immunization. Furthermore, blood draws are difficult and 
often lead to the death of the animal. 
In conclusion, the obtained results boost the interest in using recombinant MOG to assess the 
presence of Ab in the mice model of MS. The use of a proven animal model has numerous 
advantages, as it enables to plan the desired experiments aimed to explore a peculiar aspect of the 
disorder, and to have a large number of samples to be analyzed. The results presented are 
preliminary and therefore will require further investigations to better understand the molecular 
mechanisms underlying the immunological response to MOG in MS. A limitation of this study is 
represented by the execution of tests on temporally distinct cohorts, making the obtained data not 
entirely homogeneous. However, we demonstrated the lack of evidence of an epitope spreading 
mechanism related to MOG sequence. Based on these findings, future developments of this work 
will include focused and detailed studies aimed to disclose the putative pathologic role of the anti-
MOG immunological response. Specifically, the existence of a correlation between anti-MOG Ab 
and disease course, or response to pharmacological therapy, will be evaluated. Furthermore, the 
intriguing theory of a protective role of anti-MOG IgM response will be deepened. 
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Materials & Methods 
Serum samples 
90 EAE induced mice serum samples (provided by Dr. Rina Aharoni, Weizmann Institute, Rehovot, 
Israel) were analyzed, divided according to disease status. 29 naïve mice serum samples were used 
as healthy control group. Samples were tested in triplicate with a single dilution (1:100) in FBS 
Buffer.  
 
Antigens 
Recombinant rMOG1-117 was produced according to the protocol published by Gori et al118. Peptide 
probes were synthesized at the French-Italian Laboratory of Peptide and Protein Chemistry & 
Biology (PeptLab), University of Florence and University of Cergy-Pontoise. 
 
Enzyme-Linked Immunosorbent Assay (ELISA) 
1 microgram (ug)/well of Ag (peptide or protein) were dissolved in Coating Buffer (12mM Na2CO3, 
35mM NaHCO3, pH 9.6), then 100 microliter (ul) of solution were dispensed in each well of 96-
well Maxisorp plates. Plates were incubated @4°C ON. Subsequently, plates were washed 3 times 
with Washing Buffer (0,9% NaCl, 0,01% Tween 20), and blocked 1 h at room temperature (RT) with 
100ul/well of FBS Buffer (10% FBS in Washing Buffer). FBS Buffer were removed, and 100ul/well 
of diluted sera sample (1:100 in FBS Buffer) were dispensed. Blank wells were included in all the 
plates, and were obtained using FBS Buffer instead of serum. Plates were incubated @4°C ON, and 
then washed 3 times with Washing Buffer. 100ul/well of secondary Ab diluted in FBS Buffer (mIgG 
1:30000 and mIgM 1:7500) were dispensed, and plates were incubated 3 h at RT. Plates were 
washed 3 times with Washing Buffer, then 100ul/well of Substrate Solution (1mg/ml p-PNP in 
Substrate Buffer: 1M Diethanolamine, 1mM MgCl2, pH 9.8) were dispensed. Plates were incubated 
for 15’-40’, and then ABS at 405 nm of each well was red with a spectrophotometer. ABS value for 
each serum was calculated as (mean ABS of triplicate) – (mean ABS of blank triplicate).  
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PART II: EVALUATION OF MOG-IgG 
AND CSF114(Glc)-IgG AS ADDITIONAL 
NMO BIOMARKERS 
As already noted, NMO is an inflammatory demyelinating disorder of CNS, characterized by the 
presence a specific disease BM (an auto-Ab of the IgG class directed against AQP4), which is present 
in approximately 70% of NMO pts72. Therefore, the evaluation of other NMO BM may be useful to 
perform a more accurate diagnosis. The potential role of anti-MOG IgG as additional NMO BM was 
taken into account, but the studies done so far failed to give definitive results on this topic.  
In this context, we assessed the presence of a specific IgG reactivity against MOG testing NMO pts 
sera in SP-ELISA. As NMO is an MS-related disorder, we tested the same sera on CSF114(Glc), 
which is an antigenic probe able to detect disease-specific Ab response in RRMS. Results obtained 
for both Ag were compared with NBD. 
 
Results & Discussion 
IgG reactivity to rMOG1-117(His)6 is shown in Figure 22. Results obtained indicate that IgG reactivity 
to MOG is not increased in pts compared with NBD, disclosing that anti-MOG IgG is not a reliable 
BM in the case of NMO. However, we noted that Ab titer in AQP- pts is higher than in AQP+ (Figure 
23), even if both the NMO groups have lower anti-MOG IgG values compared with NBD. 
Results obtained testing the antigenic probe CSF114(Glc) on both NMO and NBD sera (Figure 24) 
show that there is no significant difference between pts and healthy controls, disclosing that anti-
CSF114(Glc) IgG is not a BM in the case of NMO. This finding further confirms that NMO and MS 
are two distinct pathologies, characterized by different serological profiles. 
Concluding, our study demonstrates that anti-MOG IgG are not present in NMO pts. The use of the 
properly refolded rat isoform of the extracellular domain of the protein, which shares a >90% 
homology with the human one, could represent a limitation of this work. Indeed, rMOG has a Ser 
in position 42, while hMOG has a Pro: this could lead to both structural and immunogenicity 
differences. It may be useful to repeat the test comparing anti-rMOG and anti-hMOG Ab titer. 
Furthermore, the absence of anti-CSF114(Glc) IgG in NMO pts provides an additional evidence of 
the different pathological profile of MS and NMO. One of the further developments of this work 
may be represented by the enlargement of both NMO and NBD cohorts, in order to obtain more 
reliable data, to be compared with the one previously achieved for MS. 
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Figure 22: IgG reactivity to rMOG1-117(His)6 in NMO (left) and NBD (right).  
Cutoff value is represented with a dotted line. 
 
 
Figure 23: IgG reactivity to rMOG1-117(His)6 in the tested sera group.  
From left: AQP4+ NMO pts, AQP4- NMO pts, NBD. 
 
 
Figure 24: IgG reactivity to CSF114(Glc) in NMO (left) and NBD (right).  
Cutoff value is represented with a dotted line. 
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Materials & Methods 
Serum samples 
21 NMO pts serum samples (provided by Prof. Jerome De Seze, Hôpitaux universitaires de 
Strasbourg, France) were analyzed, divided according to disease status. 20 NBD serum samples 
were used as healthy control group. Samples were tested in triplicate with a single dilution (1:100) 
in FBS Buffer.  
 
Antigens 
Recombinant rMOG1-117 was produced according to the protocol published by Gori et al118. Peptide 
probe was synthesized at the French-Italian Laboratory of Peptide and Protein Chemistry & Biology 
(PeptLab), University of Florence and University of Cergy-Pontoise. 
 
Enzyme-Linked Immunosorbent Assay (ELISA) 
1ug/well of Ag (peptide or protein) were dissolved in Coating Buffer (12mM Na2CO3, 35mM 
NaHCO3, pH 9.6), then 100 ul of solution were dispensed in each well of 96-well Maxisorp plates. 
Plates were incubated @4°C ON. Subsequently, plates were washed 3 times with Washing Buffer 
(0,9% NaCl, 0,01% Tween 20), and blocked 1 h at RT with 100ul/well of FBS Buffer (10% FBS in 
Washing Buffer). FBS Buffer were removed, and 100ul/well of diluted sera sample (1:100 in FBS 
Buffer) were dispensed. Blank wells were included in all the plates, and were obtained using FBS 
Buffer instead of serum. Plates were incubated @4°C ON, and then washed 3 times with Washing 
Buffer. 100ul/well of secondary Ab diluted in FBS Buffer (hIgG 1:8000 and hIgM 1:1200) were 
dispensed, and plates were incubated 3 h at RT. Plates were washed 3 times with Washing Buffer, 
then 100ul/well of Substrate Solution (1mg/ml p-PNP in Substrate Buffer: 1M Diethanolamine, 
1mM MgCl2, pH 9.8) were dispensed. Plates were incubated for 15’-40’, and then ABS at 405 nm 
of each well was red with a spectrophotometer. ABS value for each serum was calculated as (mean 
ABS of triplicate) – (mean ABS of blank triplicate).  
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PART III: IMMUNOLOGICAL ROLE OF 
MOG IN NMO-LIKE EAE RAT MODELS 
As previously noted, the obtainment of a specific Rattus Norvegicus NMO-like EAE model was 
achieved immunizing Brown Norway rats with recombinant, not-refolded rMOG1-117(His)6 
produced in our lab. In particular, it was analyzed the possibility to reproduce the disorder 
administering two doses of immunizing agent (together with adjuvant). The aim of this study was 
to evaluate the Ab response elicited in the NMO-like model to disclose the correlation between anti-
MOG Ab titer and disease progression. A first attempt to evaluate the model obtained immunizing 
Brown Norway rats with rMOG1-117(His)6 was made studying the time-course of IgM and IgG anti-
MOG Ab response. Subsequently, it was assessed the correlation between Ab titer against refolded 
MOG and both time- and disease-course in four different immunization protocols. The same cohort 
was examined to verify the presence of a response against unfolded MOG and CSF114(Glc). 
Results & Discussion 
11 EAE rat serum samples collected in different days post immunization (DPI) were tested in SP-
ELISA against rMOG1-117(His)6. Results obtained were compared with 3 naïve rat samples (Figure 
25). Data obtained confirmed the presence of a canonical Ab response, with the IgM peak at day 10 
and the IgG peak around day 45. 
 
Figure 25: IgM and IgG response to rMOG1-117(His)6.  
Anti-MOG Ab time-course is shown on the right. 
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A second rat cohort was tested to assess the correlation between anti-MOG titer and disease 
progression in four distinct models. Animals were immunized with recombinant, unfolded rMOG1-
117(His)6, then divided in 4 groups:  
1. No further immunization; 
2. Boost at day 39 with PBS; 
3. Boost at day 39 with rMOG1-117(His)6; 
4. Boost at day 50 with rMOG1-117(His)6. 
Serum samples were collected from at day 42, 51 and 77 post immunization, and tested against 
rMOG1-117(His)6. Results obtained are shown in Figure 26 and Figure 27 . 
Rats that received one single immunization with the protein have a disease score = 0 throughout 
the observation period, and developed a stable anti-MOG Ab response (both IgM and IgG) after the 
administration of the protein. These findings indicate that the first immunization with the protein 
triggers a strong humoral response, which however is not correlated with disorder occurrence or 
progression. Similar results were achieved in the animals boosted with PBS alone, which in turn 
did not exhibit pathological signs. 
In the case of double-immunization, rats developed a disease score = 4-5 after the boost. We 
observed that IgG titers are high and stable in time, in agreement with the previously mentioned 
results that disclose the IgG peak around day 45 post-immunization (Figure 25). Therefore, the 
anti-MOG IgG detected still refers to the first immunization step. In the case of IgM, we noticed a 
high increase in the Ab titer in 3/5 animals.  
From a molecular point of view, it appears that a single immunization with the recombinant is 
rMOG1-117(His)6 is not sufficient to induce the disease in Brown Norway rats, even if it is able to 
elicit an Ab response. Conversely, animals boosted with a second dose of protein develop a severe 
NMO-like disorder, corresponding to a rise of the anti-MOG IgM titer. Based on these findings, we 
can hypothesize two different scenarios: 
 the anti-MOG response is not correlated with disease progression, and therefore the 
detected Ab have not a pathologic role; 
 there are two families of anti-MOG Ab, and only one is responsible for disease occurrence. 
We are not able to distinguish them because we used a full-length recombinant protein, 
which contains different epitopes, both conformational and linear.  
In the latter case, it would be interesting to investigate the epitope of the two families through an 
epitope mapping study, using both solid phase and competitive ELISA. Summarizing, we 
demonstrated that a NMO-like model can be obtained immunizing Brown Norway rats with 
recombinant rMOG1-117(His)6. This result allows us to speculate a role of this protein in the disorder, 
even if we obtained contrasting data in human NMO. As already stated, this may be due to the use 
of recombinant rMOG as Ag in the tests with human sera: the two isoforms share a high degree of 
homology in terms of sequence, but some of the not conserved Aa may be crucial for both 
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conformation and immunogenicity, affecting the Ab recognition. The relevance of this difference in 
the primary sequence will be elucidated testing in parallel rMOG and hMOG as Ag, and comparing 
the obtained data. However, it must be kept in mind that both the results achieved studying NMO 
and the rat NMO-like model are preliminary, and therefore further clarifications and investigations 
are needed.  
 
The same sera cohorts were tested also against unfolded rMOG1-117(His)6 and CSF114(Glc). 
Preliminary results are show in Figure 28 (IgM response) and Figure 29 (IgG response). The Ab 
response detected against refolded and unfolded recombinant protein is slightly different, 
indicating that the conformation is maintained during the ELISA coating step. However, this 
difference is not statistically relevant, and does not allow us to speculate the presence of 
conformational epitopes. Concerning CSF114(Glc), we have not detected any IgG response against 
this probe, coherently with the data obtained in the human NMO pathology (Figure 24). 
Conversely, the anti-CSF114(Glc) IgM response is detectable in the model regardless of the 
immunization protocol, with a trend mirroring that of MOG. This pattern of Ab response against 
the glucosylated peptide (namely, presence of IgM and absence of IgG) may indicate a sort of 
epitope spreading starting from the immunizing agent.  
As stressed also in the case of EAE mice model of MS, the use of animal models in both clinical and 
immunological field is of crucial relevance, as it enables to understand numerous aspects that 
would otherwise be out of reach. The obtainment of a suitable NMO-like EAE animal model may 
allow to disclose the molecular mechanisms characterizing this CNS AID, and in particular to clarify 
the immunopathogenic role of both AQP4 and MOG. However, further investigations on the Ab 
response of the NMO-like model are required to formulate a precise hypothesis of 
immunopathogenic molecular mechanism characterizing the disorder. 
  
Chapter 2 
 
48 
 
Figure 26: IgM response to rMOG1-117(His)6 in the different cohorts: not boosted rats (black);  
boosted at day 39 with PBS (red); boosted at day 39 with rMOG1-117(His)6 (blue);  
boosted at day 50 with rMOG1-117(His)6. 
 
 
Figure 27: IgG response to rMOG1-117(His)6 in the different cohorts: not boosted rats (black);  
boosted at day 39 with PBS (red); boosted at day 39 with rMOG1-117(His)6 (blue);  
boosted at day 50 with rMOG1-117(His)6. 
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Figure 28: IgM titers against refolded rMOG1-117(His)6 (green), unfolded rMOG1-117(His)6 (blue) and 
CSF114(Glc) (yellow) in the 4 different immunization protocols:  
not boosted (1N, 2N, 3N), boosted at day 39 with rMOG1-117(His)6 (1B, 2B, 3B),  
boosted at day 39 with PBS (1R, 2R, 3R), boosted at day 50 with rMOG1-117(His)6 (1V, 2V, 3V). 
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Figure 29: IgG titers against refolded rMOG1-117(His)6 (green), unfolded rMOG1-117(His)6 (blue) and 
CSF114(Glc) (yellow) in the 4 different immunization protocols:  
not boosted (1N, 2N, 3N), boosted at day 39 with rMOG1-117(His)6 (1B, 2B, 3B),  
boosted at day 39 with PBS (1R, 2R, 3R), boosted at day 50 with rMOG1-117(His)6 (1V, 2V, 3V). 
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Materials & Methods 
Serum samples 
50 EAE induced rat serum samples (provided by Prof. Jerome De Seze group (Hôpitaux 
universitaires de Strasbourg, France) were analyzed, divided according to the immunization 
protocol. Samples were tested in triplicate with a single dilution (1:100) in FBS Buffer.  
 
Antigens 
Recombinant refolded rMOG1-117 was produced according to the protocol published by Gori et al118. 
Recombinant unfolded rMOG1-117 was obtained modifying the purification protocol as follows. 
Solubilized IB sample was loaded in column and washed with:  
1. 50 ml Buffer A (100 mM NaH2PO4, 10 mM Tris, 6M GuaCl) pH 8; 
2. 50 ml Buffer A pH 6; 
3. 50 ml Buffer A pH 5.2. 
Elution was performed using Buffer A pH 4.5.  
Peptide probes were synthesized at the French-Italian Laboratory of Peptide and Protein Chemistry 
& Biology (PeptLab), University of Florence and University of Cergy-Pontoise. 
 
Enzyme-Linked Immunosorbent Assay (ELISA) 
1ug/well of Ag (peptide or protein) were dissolved in Coating Buffer (12mM Na2CO3, 35mM 
NaHCO3, pH 9.6), then 100 ul of solution were dispensed in each well of 96-well Maxisorp plates. 
Plates were incubated @4°C ON. Subsequently, plates were washed 3 times with Washing Buffer 
(0,9% NaCl, 0,01% Tween 20), and blocked 1 h at RT with 100ul/well of FBS Buffer (10% FBS in 
Washing Buffer). FBS Buffer were removed, and 100ul/well of diluted sera sample (1:100 in FBS 
Buffer) were dispensed. Blank wells were included in all the plates, and were obtained using FBS 
Buffer instead of serum. Plates were incubated @4°C ON, and then washed 3 times with Washing 
Buffer. 100ul/well of secondary Ab diluted in FBS Buffer (rIgG 1:5000 and rIgM 1:5000) were 
dispensed, and plates were incubated 3 h at RT. Plates were washed 3 times with Washing Buffer, 
then 100ul/well of Substrate Solution (1mg/ml p-PNP in Substrate Buffer: 1M Diethanolamine, 
1mM MgCl2, pH 9.8) were dispensed. Plates were incubated for 15’-40’, and then ABS at 405 nm 
of each well was red with a spectrophotometer. ABS value for each serum was calculated as (mean 
ABS of triplicate) – (mean ABS of blank triplicate).  
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PART IV: OPTIMIZATION OF rMOG1-117  
PRODUCTION PROCESS 
As stated in the introductive chapter, Ag production process is a key step of the BM research in both 
diagnostic and prognostic fields. As mentioned several times during this presentation, MOG is the 
most studied candidate Ag in the case of CNS AID, and therefore the production of this protein as 
antigenic probe is of crucial relevance to study the immunopathogenesis of disorders such as MS 
or NMO. In our lab, we decided to employ recombinant rMOG1-117, which was obtained through the 
expression and purification protocol published by Gori et al.118. This methodology includes 
numerous laborious and time-consuming phases that invalidate productivity. Therefore, the aim of 
this project was to improve rMOG1-117 production process, focusing on the optimization of both 
expression in E.coli and purification/on-column refolding of the protein. 
 
Results & Discussion 
The recombinant rat protein rMOG1-117 was primarily expressed, purified and refolded according to 
the protocol published by Gori et al.118. This methodology was very effective, but included some 
laborious and lengthy steps. Therefore, the method was improved optimizing the following steps: 
1. E.coli cells 
The previous protocol was carried out employing ER2566 electrocompetent E.coli cells, 
which give high transformation efficiencies using a quick method. However, the procedure 
requires specialized apparatus and cuvettes, and is salt-sensitive. The use of chemically 
competent cells leads to both simplification of the protocol and cost reduction, as no special 
equipment is necessary and cells are less expensive. Furthermore, the selected BL21(DE3)-
Gold cells are ultra-competent, thus allowing the obtainment of transformation efficiencies 
comparable with the one achieved using electrocompetent cells. 
 
2. IB solubilization 
The original protocol provided 5 steps of sonication-centrifugation-resuspension with 
Potter. In particular, the resuspension part is laborious, time-consuming and requires skills 
with the instrument. Additionally, the final product has to be resuspended by a ≈90’ stirring 
and then centrifuged again before the purification.  
A first attempt for improvement was made changing resuspension buffer composition 
(which consisted of Tris and NaCl) by the addition of a denaturant (GuaCl) and a detergent 
(Triton X-100), in order to facilitate the solubilization. Furthermore, the number of 
sonication-centrifugation-resuspension steps was reduced from 5 to 3. Unfortunately, the 
new method was still disadvantageous, as the Potter resuspension was still required, and 
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the final stirring step was not removed. Furthermore, the obtained sample was viscous, 
leading to overpressure problems of and column clogging during the purification. 
Both duration and complexity of the process were considerably reduced using the next 
measures: 
- Longer sonication for time (1’ instead of 10’’); 
- Longer and at higher-rpm speed (from 17,000 to 25,000 rpm) centrifugation steps; 
- Use of Urea 8M and ≈30’ stirring for solubilization. 
These modifications enable to obtain a soluble sample to be purified with only 2 
centrifugation steps and 1 resuspension by stirring. Being liquid, the lysate can be loaded 
directly into the purification system without needing dilution, and causes no problems to 
the column or to the instrument. 
3. Purification method 
The previously reported method used a Precision Column Holder to be packed with 
Chelating Sepharose Fast Flow resin and then added with NiSO4. This procedure requires 
two incubation steps of the column: the first, to facilitate the Ni2+ binding to the resin (30’) 
and the second to allow the protein sample binding to Ni2+ (2h). Furthermore, an 
approximate calculation of the protein concentration is needed, in order to estimate the 
amount of resin and NiSO4 to be loaded in column. To avoid the manual packing, which is 
laborious and time-consuming, the HisTrap FF pre-packed column was selected. This 
column is pre-charged with Ni Sepharose 6 Fast Flow, has high binding capacity 
(approximately 40 mg/ml medium) and is compatible with a wide range of additives 
(reducing agents, detergents, denaturants, ecc.). The price of the product is moderate, and 
can be further reduced recharging the exhausted column with fresh NiSO4 after an easy 
cleaning-in-place procedure. 
Another improvement concerns the use of a Superloop to introduce the lysate in the 
purification system. This step enables to fully automate the procedure, as the sample is 
injected in the column directly by the instrument. Moreover, up to 50 ml of solubilized IB 
can be purified at one time, significantly reducing the process time.  
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Materials & Methods 
rMOG1-117(His)6 expression and purification protocol  
pET-22rMOG1-117(His)6 plasmid 
pET-22rMOG1-117(His)6 plasmid (Figure 30) was obtained amplifying the 1-117 portion of MOG 
from pQE12rMOGED(His)6 plasmid and inserting it into a pET-22b vector (Novagen). 
 
Figure 30: pET-22rMOG1-117(His)6 plasmid structure (left)  
and recombinant rMOG1-117(His)6 sequence (right).  
In red, Aa added during the amplification step. In blue, the 6-His tag. 
 
ER2566 cells transformation with pET-22rMOG1-117(His)6 
ER2566 electrocompetent cells were transformed with pET-22rMOG1-117(His)6 using the 
electrophoretic transformation protocol. Briefly, 70 ul of cells were added to 1 ul of plasmid (120 
ng/ul), then the suspension was transferred into a 1 mm cuvette and electroporated (2000 V, 5 ms). 
Immediately, 300 ul of SOC medium were added to the cells. The obtained suspension was 
incubated at 37°C for 1 h with vigorous shaking, then 50 or 100 ul were plated on pre-warmed 
selective plates (LB Amp+) and incubated overnight (ON) at 37°C. Single colonies were picked and 
inoculated in 2 ml of LB each. The precultures (PC) were incubated ON at 37°C with vigorous 
shaking.  
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Precultures and Expression Test 
Colonies were chosen to prepare PC. 5 ml of LB medium containing Ampicillin were inoculated 
with one single colony and incubated ON at 37°C with vigorous shaking. Then 6 ml of LB medium 
containing Ampicillin were inoculated with 6 ul of PC, and incubated at 37°C with vigorous shaking 
until an OD600nm between 0.4 and 0.8 (log-phase) was reached. Afterwards, 1 ml of each suspension 
was collected as not-induced sample (NI) and the remaining culture was induced with 5 ul of IPTG 
(final concentration: 1 mM) and incubated ON at 37°C with vigorous shaking. 1 ml of each induced 
culture was collected (I). NI and I samples were centrifuged at 1700o rpm for 30’ at 4°C, then the 
pellet was resuspended in 50 ul of Laemmli Buffer, heated at 100°C for 10’ and loaded on 16% SDS-
PAGE (Sodium Dodecyl Sulphate PolyAcrilamide Gel Electrophoresis). 
 
Large-scale protein expression 
1 ml of PC was inoculated in 1 L of LB medium containing Ampicillin, then incubated at 37°C with 
vigorous shaking until an OD600nm between 0.4 and 0.8 (log-phase) was reached. Afterwards, 1 ml 
of each suspension was collected as not-induced sample (NI) and the remaining culture was 
induced with 5 ul of IPTG (final concentration: 1 mM) and incubated ON at 37°C with vigorous 
shaking. 1 ml of each induced culture was collected (I). NI and I samples were centrifuged at 1700o 
rpm for 30’ at 4°C, then the pellet was resuspended in 50 ul of Laemmli Buffer, heated at 100°C for 
10’ and loaded on 16% SDS-PAGE. 
 
Cell lysis and IB solubilization 
The ON 1 L culture was centrifuged for 30’ at 4°C, 4000 rpm. The pellet was resuspended in 10 ml 
of Soni Buffer pH 8 (50 mM Tris, 300 mM NaCl) containing protease inhibitor (500 ul of a solution 
obtaining dissolving a tablet of Complete, EDTA-free protease inhibitor in 2 ml of milliQ H2O), then 
stored at -20°C if not immediately used for the following steps. The suspension was added with a 
tip of lysozyme, then stirred for at least 30’ at RT. LDAO was added (0,83 ml/50 ml of culture), 
then: 
1. The suspension was sonicated on ice (10x30’’, power=50%) and centrifuged for 30’ at 
4°C, 17000 rpm.  
2. The pellet was resuspended* in 10 ml of Soni Buffer + LDAO 0,5%. 
3. The suspension was sonicated on ice (10x30’’, power=50%) and centrifuged for 20’ at 
4°C, 17000 rpm.  
4. The pellet was resuspended* in 10 ml of Soni Buffer + LDAO 0,5%. 
5. The suspension was sonicated on ice (10x30’’, power=50%) and centrifuged for 20’ at 
4°C, 17000 rpm.  
6. The pellet was resuspended* in 10 ml of Soni Buffer + LDAO 0,5%. 
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7. The suspension was sonicated on ice (10x30’’, power=50%) and centrifuged for 20’ at 
4°C, 17000 rpm.  
8. The pellet was resuspended* in 10 ml of Soni Buffer. 
9. The suspension was sonicated on ice (10x30’’, power=50%) and centrifuged for 20’ at 
4°C, 17000 rpm.  
10. The pellet was resuspended* in 10 ml of Soni Buffer. 
11. The suspension was sonicated on ice (10x30’’, power=50%) and centrifuged for 20’ at 
4°C, 17000 rpm. 
 * Resuspension steps are performed with Potter. 
The obtained pellet (IB) was solubilized adding 500 ul of Soni Buffer and then 5 ml of Buffer A + 
40 mM β-mercaptoethanol, βME, pH 8 (100 mM NaH2PO4, 10 mM Tris, 6M GuaCl, 40 mM βME) 
and stirring for 30-90’ at RT. The suspension was centrifuged at 17000 rpm for 30’ at RT. 
 
Purification and refolding by affinity chromatography 
Precision Column Holder XK16 was packed with Chelating Sepharose Fast Flow resin, then 
connected with ÄktaBasic chromatograph system. The column was washed with milliQ H2O, 
disconnected and added with NiSO4, then stirred for 30’ at RT. The column was connected again 
with ÄktaBasic chromatograph system and washed with milliQ H20, then equilibrated with Buffer 
A + 1 mM βME pH 8 (100 mM NaH2PO4, 10 mM Tris, 6M GuaCl, 1 mM βME). 
Previously obtained sample was diluted with Buffer A pH 8 (100 mM NaH2PO4, 10 mM Tris, 6M 
GuaCl), in order to obtain a 2-3 mM βME final concentration. Sample was loaded into the column, 
then stirred for 2 h at RT. The column was packed by gravity and connected with ÄktaBasic 
chromatograph system. Purification and refolding method is the following (flow: 1 ml/min): 
a) Refolding. Gradient (600’): 100% Buffer A → 100% Buffer B + GSH pH 8 (100 mM 
NaH2PO4, 10 mM Tris, 3mM GSH) 
b) Gradient (120’). 100% Buffer B + GSH → 100% Buffer B (100 mM NaH2PO4, 10 mM 
Tris) 
c) Elution. 100% EluBuffer pH 8 (100 mM NaH2PO4, 10 mM Tris, 200 mM NaCl, 500 mM 
Imidazole). 
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rMOG1-117(His)6 expression and purification protocol optimization 
BL21(DE3) cells chemical transformation with pET-22rMOG1-117(His)6 
BL21(DE3) cells were transformed with pET-22rMOG1-117(His)6 using the chemical transformation 
protocol. Briefly, 100 ul of cells were added to 1-50 ng of plasmid and incubated on ice for 30’, then 
heat shocked for 20’’-1’ in a 42°C water bath without shaking and incubated on ice again for at least 
2’. 900 ul of pre-warmed LB medium were added to each cell aliquot, and then the suspensions 
were incubated at 37°C for 1 h at 225 rpm. 100 ul of each suspension were plated on pre-warmed 
selective plates (LB Amp+) and incubated ON at 37°C.Single colonies were picked and inoculated 
in 2 ml of LB each. The PC were incubated ON at 37°C with vigorous shaking.  
 
Precultures and Expression Test 
Colonies were chosen to prepare PC. 5 ml of LB medium containing Ampicillin were inoculated 
with one single colony and incubated ON at 37°C with vigorous shaking. Then 6 ml of LB medium 
containing Ampicillin were inoculated with 6 ul of PC, and incubated at 37°C with vigorous shaking 
until an OD600nm between 0.4 and 0.8 (log-phase) was reached. Afterwards, 1 ml of each suspension 
was collected as not-induced sample (NI) and the remaining culture was induced with 5 ul of IPTG 
(final concentration: 1mM) and incubated ON at 37°C with vigorous shaking. 1 ml of each induced 
culture was collected (I). NI and I samples were centrifuged at 1700o rpm for 30’ at 4°C, then the 
pellet was resuspended in 50ul of Laemmli Buffer, heated at 100°C for 10’ and loaded on 16% SDS-
PAGE. 
 
Large-scale protein expression 
1 ml of PC was inoculated in 1 L of LB medium containing Ampicillin, then incubated at 37°C with 
vigorous shaking until an OD600nm between 0.4 and 0.8 (log-phase) was reached. Afterwards, 1 ml 
of each suspension was collected as not-induced sample (NI) and the remaining culture was 
induced with 5 ul of IPTG (final concentration: 1 mM) and incubated ON at 37°C with vigorous 
shaking. 1 ml of each induced culture was collected (I). NI and I samples were centrifuged at 1700o 
rpm for 30’ at 4°C, then the pellet was resuspended in 50ul of Laemmli Buffer, heated at 100°C for 
10’ and loaded on 16% SDS-PAGE. 
 
  
Chapter 2 
 
58 
Evaluation of the best strategy for cell lysis and IB solubilization 
Method #1  
The ON 1 L culture was centrifuged for 30’ at 4°C, 4000 rpm. The pellet was resuspended in 10 ml 
of Tris 20 mM pH 8 containing protease inhibitor (500ul of a solution obtaining dissolving a tablet 
of Complete, EDTA-free protease inhibitor in 2 ml of milliQ H2O), then stored at -20°C if not 
immediately used for the following steps. The suspension was sonicated on ice (4 x 10’’, 
power=60%) and centrifuged for 10’ at 4°C, 17000 rpm. The pellet was resuspended* in 10 ml of 
cold IB Solubilization Buffer pH 8 (2M GuaCl, 20 mM Tris, 0.5 M NaCl, 2% Triton X-100) then 
sonicated on ice (4 x 10’’, power=60%) and centrifuged for 10’ at 4°C, 17000 rpm. The pellet was 
resuspended* in 10 ml of cold IB Solubilization Buffer pH 8 then sonicated on ice (4 cycles of 10’’, 
power=60%) and centrifuged for 10’ at 4°C, 17000 rpm. The pellet was resuspended* in 10 ml of 
cold IB Solubilization Buffer pH 8 without GuaCl (20 mM Tris, 0.5 M NaCl, 2% Triton X-100) then 
sonicated on ice (4 x 10’’, power=60%) and centrifuged for 10’ at 4°C, 17000 rpm. The pellet 
obtained can be used immediately for purification or conserved at -20°C. The IB pellet was 
resuspended in 10 ml of Binding Buffer pH 8 with βME (GuaCl 6M, NaH2PO4 0.1 M, 10 mM Tris, 
0.5 M NaCl, 20 mM Imidazole, 20 mM βME) by stirring for 60-90’ at RT, then centrifuged for 15’ 
at RT, 17000 rpm 
* The resuspension steps are performed with Potter. 
 
Method #2  
The overnight cultures were centrifuged at 4000 rpm for 30’ at 4°C. The pellet was resuspended in 
10 ml of 20 mM Tris pH 8 containing protease inhibitor (500 ul of a solution obtaining dissolving 
a tablet of Complete, EDTA-free protease inhibitor in 2 ml of milliQ H2O), then stored at -20°C if 
not immediately used for the following steps. The suspension was sonicated (3 x 1’, 40% amplitude, 
repeated twice) and centrifuged at 25000 rpm for 65’ at 4°C. The supernatant (called “1st 
supernatant”) was collected to evaluate the possible presence of the protein, and the pellet was 
resuspended in the same amount of Urea 8M. The sample was sonicated and centrifuged again. 
The supernatant (called “2nd supernatant”) was collected to evaluate the possible presence of the 
protein, and the pellet was resuspended in the same amount of Urea 8M. The sample obtained was 
called “Solubilised IB”. 20 ul of each sample were added with 5 ul of 5X Laemmli Buffer, heated at 
100°C for 10’ and loaded on 16% SDS-PAGE. After the SDS-PAGE run, is evident that the protein 
is absent in the 1st supernatant, while the largest amount is located in the 2nd wash. This sample 
was used for the purification step. 
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Purification and refolding by affinity chromatography 
The purification steps are performed using ÄktaBasic chromatograph system and the HisTrap FF 1 
ml column (GE Healthcare). Purification and refolding method is the following: 
1) Column equilibration. 15 CV Binding Buffer pH 8 (6 M GuaCl, 0.1 M NaH2PO4, 10 mM 
Tris, 0.5 M NaCl, 20 mM Imidazole) 
2) Sample Injection 
3) Conditioning. 15 CV Binding Buffer pH 8. The UV signal must be stable 
4) Refolding. Gradient (600’): 100% Binding Buffer pH 8 → 100% GSH Buffer pH 8 (6 M 
GuaCl, 0.1 M NaH2PO4, 10 mM Tris, 0.5 M NaCl, 20 mM Imidazole, 3 mM GSH) 
5) Wash (60’). GSH Buffer pH 8 
6) Gradient (150’). 100% GSH Buffer pH 8 → 100% Washing Buffer (0.1 M NaH2PO4, 10 
mM Tris, 0.5 M NaCl, 20 mM Imidazole) 
7) Wash. 5 CV Washing Buffer  
8) Elution. Gradient (20 CV): 100% Washing Buffer → 100% Elution Buffer (6 M GuaCl, 
0.1 M NaH2PO4, 10 mM Tris, 0.5 M NaCl, 500 mM Imidazole ) 
9) Continue the Elution with 100% Elution Buffer.  
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PART V: SEMI-SYNTHESIS OF 
ABERRANTLY N-GLUCOSYLATED 
hMOG1-117 
As stated above, the involvement of aberrant PTM on MOG in triggering CNS autoimmunity is a 
crucial topic. In this context, we hypothesized that an aberrant N-glucosylation on the MOG native 
site of glycosylation (Asn31) may be involved in the immunopathogenesis of CNS demyelinating 
disorders. For this purpose, it was decided to produce the hMOG35-117 fragment using molecular 
biology tools, engineering the sequence to obtain the N-terminal free Cys. Specifically, a selective 
point mutation was introduced at the 35 residue (M35C) and the sequence was extended at the N-
terminus with the TEV-protease consensus sequence. The C-terminal active ester of the peptide 
fragment [Asn31(Glc)]hMOG(1-34) was prepared at the SOSCO Laboratory (Universitè de Cergy 
Pontoise, France). 
 
Results & Discussion 
To perform NCL, the native sequence of hMOG35-117, reported on data bank, was modified with a 
selective point mutation (M35→C35) and extended with the consensus sequence of TEV at the N-
terminus. Furthermore, a 6-His tag was added at the C-terminus to enable Ni-affinity 
chromatography purification (Figure 31). The designed sequence was successfully cloned in a pET-
22b expression vector (Figure 32. Cloning steps are displayed in Materials & Methods section), as 
demonstrated by PCR (Figure 33) and sequencing (data not shown). Further confirmation was 
obtained performing a specific digestion on the purified PCR fragment (Figure 33). 
Recombinant protein expression and purification protocols were developed and selected in order 
to optimize both protein yield and process timing. In particular: 
 Expression was carried out in BL21(DE3)-Gold chemically competent E.coli cells, which enable 
a high efficiency expression level under the control of a T7 promoter. 
 It was determined that the best strategy to obtain an acceptable amount of soluble protein is 
the post-induction ON growth at RT with vigorous shaking. Classical 37°C ON growth after 
induction enables to obtain higher protein concentrations, which precipitates after purification.  
 Recombinant protein is expressed in IB. The chosen strategy to obtain solubilized IB provides 
two sonication-high speed centrifugation steps (Figure 34). The developed methodology is not 
time-consuming and enable the obtainment of the protein sample directly in solution after the 
last centrifuge. The latter feature is particularly important because it allows to easily 
manipulate the sample during the purification step and avoid column clogging. 
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Purification was performed on large-scale cultures using an Äktabasic system. The selected affinity 
columns are the prepacked HisTrap FF 1ml, which enable to perform a rapid and efficient process. 
The developed protocol allows to purify the recombinant from the lysate through a 4-step process, 
which leads to the obtainment of partially refolded protein in non-denaturing conditions. The 
identity of the purified protein was assessed by MALDI-MS (Figure 35), performed in collaboration 
with Toscana Biomarkers srl (Siena), and SDS-PAGE (Figure 36). The latter analysis enabled to 
notice that a fraction of the protein is not retained in column during the wash step, as it is present 
also in the column flow-through. Therefore, the column flow was always collected, checked by SDS-
PAGE to verify the presence of MOG, and eventually loaded in column for a second purification 
round.  
 
Figure 31: Engineered hMOG35-117 sequence, (TEVconsensus)-(Cys35)hMOG1-117(His)6.  
In green, the TEV consensus sequence. In red, the mutated residue (M35C).In blue, the 6-His tag. 
 
 
Figure 32: pET-22b_(TEVconsensus)-(Cys35)hMOG1-117(His)6 vector scheme.  
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Figure 33: 1,5% agarose gels: on the left, PCR fragments obtained amplifying the plasmid  
with T7 promoter and terminator primers (desired fragment =453 bp);  
on the right PCR fragments digested with XhoI (desired fragment = 359 bp). 
 
 
Figure 34: 16% SDS-PAGE of different fractions obtained during cell lysis and IB solubilization.  
The protein is present in solution after 2 sonication-centrifugation steps. 
 
 
Figure 35: MALDI-MS analysis of (TEVconsensus)-(Cys35)hMOG1-117(His)6 protein. 
(MW = 11678 Da). 
 
 
Figure 36: 16% SDS-PAGE of (TEVconsensus)-(Cys35)hMOG1-117(His)6 protein. In the first lane, the 
solubilized IB sample loaded in column, then the column flow-throughs  
and the purified fractions. 
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To obtain the free N-terminal Cys35 required for NCL, several TEV-cleavage attempts were 
performed. In particular, the following variables were adjusted to maximize the amount of cut 
protein: units of enzyme (U), cleavage buffer composition, incubation time and temperature. 
Samples obtained after cleavage reaction were run on 16%-4% SDS or 18%-5% Tricine PAGE, in 
order to verify the cleavage. Since gels have not enabled the detection of two distinct bands (cut and 
uncut protein), it was necessary to perform MALDI-MS analyses on the samples. Another useful 
methodology to monitor the cleavage reaction is analytical HPLC-MS. This technique requires 
small sample volume, is fast and relatively inexpensive. Furthermore, it allows to follow the 
reaction course observing the protein molecular weight, provided by MS. Using both MALDI-MS 
and HPLC, we established that the best cut protein yield was obtained using 200 U of TEV/100 ug 
of protein, and incubating the reaction ON at 20°C in a buffer containing 2 M Urea and 14 mM 
βME. In spite of the numerous different reaction conditions tested, we have not obtained high yield 
of (Cys35)-hMOG35-117. Indeed, all the samples analyzed are composed by a mixture of cut and uncut 
protein, and the latter was always the most abundant. To overcome this problem, we decided to 
purify selectively the cut protein (Cys35)-hMOG35-117 using semi-preparative HPLC. 
Further developments of this work include: 
 ligation reaction implementation; 
 purification of the semi-synthetic protein;  
 use of the semi-synthetic construct as antigenic probe in SP-ELISA tests aimed to clarify 
the role of aberrant N-glucosylation on MOG. 
The development of a methodology allowing the obtainment of N-glucosylated MOG is crucial to 
investigate the involvement of aberrant PTM in the ethiopathogenesis of CNS AID, and to elucidate 
the role of MOG as putative auto-Ag. The use of NCL enables to combine the advantages of E.coli 
expression and SPPS, but requires considerable skills in both techniques. Furthermore, the large 
number of steps and the significant time necessary to execute and setup the method may invalidate 
the feasibility of this technique. To overcome these issues, preliminary tests were performed using 
advanced molecular biology tools. In particular, a plasmid encoding the H. influenza 
glycosyltransferase HMW1C (kindly provided by Prof. Barbara Imperiali, Massachusetts Institute 
of Technology, Cambridge) was employed to perform a double chemical transformation on 
BL21(DE3)-Gold E.coli cells, together with pET-22rMOG1-117(His)6 plasmid. Indeed, rMOG 
sequence includes the consensus sequence sequon Asn-X-Thr required for in vivo glycosylation 
operated by HMW1C. Unfortunately, the attempts performed using the HMW1 N-glucosylation 
standard protocol have not succeeded, possibly because of the protein expression at the IB level. 
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Materials & Methods 
Chemical Transformation of DH5 cells with pET-22b and pMAT-
(TEVconsensus)-(Cys35)hMOG1-117(His)6 
50 ul of chemically competent cells were transformed using two different plasmids, pET-22b 
(Novagen) and pMAT-(TEVconsensus)-(Cys35)hMOG1-117(His)6 (Life Technologies). Specifically, 2 
different mixes were prepared:  
1. DH5 cells + 10 ng of pET-22b 
2. DH5 cells + 10 ng of pMAT-(TEVconsensus)-(Cys35)hMOG1-117(His)6 
Reactions were incubated on ice for 30’, then heat-shocked at 42°C for 20’’ and incubated again on 
ice for 2’. 950 ul of LB medium was added to each reaction, and then the suspensions were 
incubated at 37°C for 1 hour with vigorous shaking. 100 ul of each suspension were plated on LB-
Agarose plates containing Ampicillin. Plates were incubated at 37°C overnight. 
 
Precultures and Midiprep of pET-22b and pMAT-(TEVconsensus)-
(Cys35)hMOG1-117(His)6 
Colonies are visible on all the plates. 2 colonies for each plasmid were chosen for PC. Briefly, each 
colony was inoculated in 3 ml of LB medium containing Ampicillin and incubated at 37°C for 8h 
with vigorous shaking. Then 50 ml of fresh medium were inoculated with 100 ul of the starter 
culture and incubated ON at 37°C for 8h with vigorous shaking. Both plasmids were purified from 
cell cultures using NucleoBond® PC100 kit (Macherey-Nagel). According to the manufacturer’s 
protocol, the cultures were centrifuged @4000 g for 30’ @4°C. The pellets were carefully 
resuspended in buffer S1+RNase A, then buffer S2 was added. The suspension were mixed by 
inverting the tubes 6-8 times. Pre-cooled buffer S3 was added, and the lysates were immediately 
mixed by inverting the tubes until a homogenous suspension containing an off-white flocculate is 
formed. Suspensions were incubated on ice for 5’. Meanwhile, NucleoBond® columns were 
equilibrated with buffer N2. Lysates were clarified using the provided folded filters, then each 
solution was loaded into a column. After the columns have emptied by gravity, buffer N3 was added 
to wash the columns. Flow-throughs were discarded. Plasmids were eluted from the columns using 
buffer N5. Each plasmid was precipitated adding RT carefully discarded, then 70% RT ethanol was 
added to each pellet. Solutions were centrifuged @15000 g for 10’ @RT, then ethanol was carefully 
removed. Pellets were allowed to dry @RT for 10’, then reconstituted with water. 
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Double Digestion of pET-22b and pMAT-(TEVconsensus)-
(Cys35)hMOG1-117(His)6 
pET-22b (cloning vector, V) and pMAT-(TEVconsensus)-(Cys35)hMOG1-117(His)6 (plasmid 
containing insert, I) were double-digested using NdeI and XhoI (NEB), using the following 
protocol: 
 pET-22b 
(V) 
pMAT-(TEVconsensus)-(Cys35)hMOG1-117(His)6 
(I) 
Reagent Volume (ul) Volume (ul) 
Buffer 4 (10X) 2.5 2.5 
BSA (100X) 0.25 0.25 
NdeI 0.5 0.5 
XhoI 0.5 0.5 
pET-22b (V) 2.5 (1 ng) - 
pMAT-(TEVconsensus)-
(Cys35)hMOG1-117(His)6 (I) 
- 1 (1 ng) 
H2O 18.75 20.25 
   
Final volume 25 25 
 
The amount of each enzyme and DNA was calculated according to the manufacturer’s instructions. 
The reactions were incubated for 3 hours at 37°C. An aliquot of each reaction was loaded into an 
1.5% Agarose gel containing Sybr Safe (Life Technologies), together with the not-digested form of 
the plasmids. The gel was run at 90 V for 1 hour. 
1) pET-22b (8ul TE buffer, 2ul DNA, 2ul Loading 
buffer 6X) 
2) Double digested pET-22b (entire reaction + 2,5ul 
Loading buffer 10X) 
3) GeneRuler 1kb Plus DNA Ladder (3 ul) 
4) pMAT-(TEVconsensus)-(Cys35)hMOG1-117(His)6 (8ul 
TE buffer, 2ul DNA, 2ul Loading buffer 6X) 
5) Double digested pMAT-(TEVconsensus)-
(Cys35)hMOG1-117(His)6 (entire reaction + 2,5ul 
Loading buffer 10X) 
6) GeneRuler 1kb Plus DNA Ladder (3 ul) 
 
DNA fragments of interest are: pET-22b, 5364 bp and pMAT-(TEVconsensus)-(Cys35)hMOG1-
117(His)6, 273 bp. Corresponding bands were cut from the gel and the DNA fragments were purified 
from agarose gel using the NucleoSpin® Gel and PCR Clean-up kit (Macherey Nagel). Obtained 
DNA fragments were loaded into 1.5% Agarose gel containing Sybr Safe, and then quantized 
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comparing the intensity of bands with GeneRuler 1kb Plus DNA Ladder. The amount of purified 
pET-22b is 20 ng/ul, and that of pMAT-(TEVconsensus)-(Cys35)hMOG1-117(His)6 is 5 ng/ul. 
 
1) Double digested pET-22b, purified from Agarose gel 
(8ul TE buffer, 2 ul DNA, 2 ul Loading buffer 6X) 
 
2) GeneRuler 1kb Plus DNA Ladder (6ul) 
 
3) Double digested pMAT-(TEVconsensus)-
(Cys35)hMOG1-117(His)6, purified from  Agarose gel 
(4ul TE buffer, 4 ul DNA, 2 ul Loading buffer 6X) 
 
 
 
 
 
Ligation of the digested fragments 
The amount of vector and insert for the ligation reaction were chosen using the following formula: 
 𝑥𝑛𝑔 𝑖𝑛𝑠𝑒𝑟𝑡 =  
𝑦𝑛𝑔 𝑣𝑒𝑐𝑡𝑜𝑟 × 𝑏𝑝𝑖𝑛𝑠𝑒𝑟𝑡
𝑏𝑝𝑣𝑒𝑐𝑡𝑜𝑟
 ×  (𝑟𝑎𝑡𝑖𝑜 𝑖𝑛𝑠𝑒𝑟𝑡: 𝑣𝑒𝑐𝑡𝑜𝑟) 
 Reaction I 
Vector: 40 ng (1:1) 
Reaction II 
Vector: 80 ng (1:1) 
Reaction III 
Vector: 40 ng (5:1) 
Reagent Volume (ul) Volume (ul) Volume (ul) 
Vector 2 4 2 
Insert  4 8 10 
Ligase Buffer 
(Fermentas) 
2 2 2 
T4 Ligase 
(Fermentas) 
2 2 2 
H2O 10 4 4 
    
Final volume 20 20 20 
 
Reactions were incubated at 16°C overnight.  
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Chemical Transformation of DH5 and XL-10 cells with ligation 
products 
200 ul of chemically competent cells were transformed using the ligation reactions. Specifically, 5 
different mixes were prepared, in order to find the best conditions: 
1. DH5 cells + 10 ul of Reaction I 
2. XL-10 cells + 10 ul of Reaction I 
3. DH5 cells + 5 ul of Reaction II 
4. XL-10 cells + 5 ul of Reaction II 
5. XL-10 cells + Reaction III. 
Reactions were incubated on ice for 1 hour, then heat-shocked at 42°C for 2’ and incubated again 
on ice for at least 5’. 1 ml of LB medium was added to each reaction, and then the suspensions were 
incubated at 37°C for 2 hours with vigorous shaking. 100 ul of each suspension were plated on LB-
Agarose plates containing Ampicillin and Nalidixic Acid. After that, reactions were centrifuged at 
5000 rpm for 5’. 100 ul of each supernatant were used to resuspend the pellet, then plated on LB-
Agarose plates containing Ampicillin and Nalidixic Acid. Plates were incubated at 37°C overnight. 
 
Colony picking and Colony PCR 
Colonies are visible on all the plates. 30 colonies from different plates were chosen to perform 
colony PCR. Briefly, each colony was picked with a sterile tip and streaked on a fresh LB-Agarose 
plates containing Ampicillin and Nalidixic Acid (transfer plate). Then the same tip was used to 
resuspend the colony in 50 ul of sterile H2O. The suspensions were incubated at 100°C for 15’, then 
at -20°C for 15’ (heat shock). Suspensions were centrifuged at 15000 g for 3’. 2 ul of each 
supernatant were carefully collected and used as template for PCR. The PCR reactions were 
prepared as follows: 
Reagent Volume (ul) Final Concentration 
10X DreamTaq Green Buffer (Fermentas) 2.5 1X 
dNTPs (Sigma Aldrich) 0.5 0.2 uM 
T7 terminator primer (Jena Biosciences) 2.5 1 uM 
T7 promoter primer (Jena Biosciences) 2.5 1 uM 
DreamTaq DNA Polymerase (Fermentas) 0.2  
DNA template 2  
H2O 14.8  
   
Final volume 25  
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In addition to DNA template from the colonies, negative controls were added (pET-22b and H2O). 
Thermocycler was set as follows: 
1. 95°C for 3’ 
2. 95°C for 30” 
3. 55°C for 30”       35 cycles 
4. 72°C for 30” 
5. 72°C for 5’ 
6. 12°C  
Samples were loaded on 1% Agarose gel. The expected band is 453 bp (pET-22b negative control: 
309 bp). 
 
PCR reactions: 
1-30 – template = colony; 31 – no template; 32 – template = pET-22b 
 
Miniprep of the ligation product 
Three clones (#15, 16 and 22) were chosen for Midiprep. Corresponding colonies from transfer 
plate were inoculated in 10 ml of LB-medium containing Ampicillin and Nalidixic Acid, then 
incubated at 37°C overnight with vigorous shaking. Each PC was divided in 2 aliquots of 5 ml and 
processed according Miniprep protocol (Qiagen). Plasmids were eluted with 50 ul of EB buffer. 
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Ligation validation: Double digestion and PCR of the prepped 
plasmids 
Prepped plasmids were double-digested using NdeI and XhoI (NEB), using the following protocol: 
Reagent Volume (ul) 
Buffer 4 (10X) 2.5 
BSA (100X) 0.25 
NdeI 0.5 
XhoI 0.5 
Plasmid 1 ng 
H2O 18.75 
  
Final volume 25 
 
The amount of each enzyme and DNA was calculated according to the manufacturer’s instructions. 
Reactions were incubated for 3 hours at 37°C. An aliquot of each reaction was loaded into an 1.5% 
Agarose gel containing Sybr Safe, together with the not-digested form of the plasmids. The gel was 
run at 90 V for 1 hour. Plasmids were also tested by PCR using T7 terminator and T7 promoter 
primers. PCR mixes were prepared as follows: 
Reagent Volume (ul) Final Concentration 
10X DreamTaq Green Buffer 2.5 1X 
dNTPs 1 0.2 uM 
T7 terminator primer 1.25 0.5 uM 
T7 promoter primer 1.25 0.5 uM 
DreamTaq DNA Polymerase 0.2  
Plasmid 0.5  
H2O 18.3  
   
Final volume 25  
 
pET-22b was processed as negative control. Thermocycler was set as follows: 
1. 95°C for 3’ 
2. 95°C for 30” 
3. 55°C for 30”        35 cycles 
4. 72°C for 30” 
5. 72°C for 5’ 
6. 12°C  
Samples were loaded on 1% Agarose gel. The expected band is 453 bp (negative control: 309 bp). 
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Ligation validation: Sequencing of the amplicons 
Bands corresponding to the insert were cut from Agarose gel and purified from agarose gel using 
the NucleoSpin® Gel and PCR Clean-up kit. Obtained DNA fragments were loaded into 1.5% 
Agarose gel containing Sybr Safe, and then quantized comparing the intensity of bands with 
GeneRuler 1kb Plus DNA Ladder. Samples were digested with XhoI to confirm the identity of the 
sequences, using the following reaction: 
Reagent Volume (ul) 
Buffer 4 (10X) 2.5 
BSA (100X) 0.25 
XhoI 0.5 
DNA fragment 5 
H2O 16.75 
  
Final volume 25 
 
After 1 hour of incubation at 37°C, samples were loaded on 2% Agarose gel. Full-lenght band is 453 
bp, while the digested fragments are 359 bp and 94 bp. Three of six samples were sent to Eurofins 
MWG Operon to be sequenced using the commercial primers T7 promoter and T7 terminator. Exact 
match between of the obtained sequence and the desired one was confirmed using BLAST (Basic 
Local Alignment Search Tool). 
 
Chemical transformation of BL21Gold(DE3) cells with pET-22b-
(TEVconsensus)-(Cys35)hMOG1-117(His)6 
200 ul of chemically competent cells were transformed using the ligation product #15A, that is pET-
22b-(TEVconsensus)-(Cys35)hMOG1-117(His)6. Specifically, 3 different mixes were prepared, in 
order to find the best conditions: 
1. BL21Gold(DE3) + 2.5 ul of plasmid 
2. BL21Gold(DE3) + 1.5 ul of plasmid 
3. BL21Gold(DE3) + 1 ul of plasmid 
Reactions were incubated on ice for 1 hour, then heat-shocked at 42°C for 2’ and incubated again 
on ice for at least 5’. 1 ml of LB medium was added to each reaction, and then the suspensions were 
incubated at 37°C for 2 hours with vigorous shaking. 100 ul of each suspension were plated on LB-
Agarose plates containing Ampicillin. After that, reactions were centrifuged at 5000 rpm for 5’. 100 
ul of each supernatant were used to resuspend the pellet, then plated on LB-Agarose plates 
containing Ampicillin. Plates were incubated at 37°C overnight. 
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Colony picking and Colony PCR 
Colonies are visible on all the plates. 13 colonies from different plates were chosen to perform 
colony PCR. Briefly, each colony was picked with a sterile tip and streaked on a fresh LB-Agarose 
plates containing Ampicillin and Nalidixic Acid (transfer plate). Then the same tip was used to 
resuspend the colony in 50 ul of sterile H2O. The suspensions were incubated at 100°C for 15’, then 
at -20°C for 15’ (heat shock). Suspensions were centrifuged at 15000 g for 3’. 2 ul of each 
supernatant were carefully collected and used as template for PCR. PCR reactions were prepared 
as previously described. Samples were loaded on 1% Agarose gel. Expected band is 453 bp. 
 
  
Precultures and Expression Test 
6 of the 13 selected colonies were chosen to prepare PC. 5 ml of LB medium containing Ampicillin 
were inoculated with one single colony and incubated ON at 37°C with vigorous shaking. Then 6 
ml of LB medium containing Ampicillin were inoculated with 6 ul of PC, and incubated at 37°C with 
vigorous shaking until an OD600nm between 0.4 and 0.8 (log-phase) was reached. Afterwards, 1 ml 
of each suspension was collected as not-induced sample (NI) and the remaining culture was 
induced with 5 ul of IPTG (final concentration: 1mM) and incubated ON at 37°C with vigorous 
shaking. 1 ml of each induced culture was collected (I). NI and I samples were centrifuged at 1700o 
rpm for 30’ at 4°C, then the pellet was resuspended in 50ul of Laemmli Buffer, heated at 100°C for 
10’ and loaded on 16% SDS-PAGE. The expected mass of (TEVconsensus)-(Cys35)hMOG1-117(His)6 
is 11,678 kDa. 
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Evaluation of the best large-scale expression strategy  
400 ml of LB medium containing Ampicillin were inoculated with 400 ul of each PC in duplicate 
(e.g. 1A and 1B are cultures prepared using the same PC), and incubated at 37°C with vigorous 
shaking until an OD600nm between 0.4 and 0.8 (log-phase) was reached. Afterwards, 1 ml of each 
suspension was collected as not-induced sample (NI) and the remaining culture was induced with 
400 ul of IPTG (final concentration: 1mM). To evaluate which is the best growth temperature for 
the protein over-expression, one of the culture prepared in duplicate (e.g. A serie) was incubated 
ON at 37°C with vigorous shaking, while the other one (e.g. B) was incubated ON at RT with 
vigorous shaking. 1 ml of each induced culture was collected (I). NI and I samples were centrifuged 
at 1700o rpm for 30’ at 4°C, then the pellet was resuspended in 50ul of 5X Laemmli Buffer, heated 
at 100°C for 10’ and loaded on 16% SDS-PAGE. The same test was performed to evaluate the best 
IPTG concentration (1mM or 0.5mM). 
 
Cell Lysis and IB Disruption 
Overnight cultures were centrifuged at 4000 rpm for 30’ at 4°C and each pellet was resuspended 
in 10 ml of 20mM Tris pH 8 containing protease inhibitor (500ul of a solution obtaining dissolving 
a tablet of Complete, EDTA-free protease inhibitor in 2 ml of milliQ H2O), then stored at -20°C if 
not immediately used for the following steps. Suspensions were sonicated (3x1’, 40% amplitude, 
repeated twice) and centrifuged at 25000 rpm for 65’ at 4°C. Supernatants (called “1st supernatant”) 
were collected to evaluate the possible presence of the protein, and the pellets were resuspended in 
the same amount of Urea 8M. Sample were sonicated and centrifuged again. Supernatants (called 
“Urea wash”) were collected to evaluate the possible presence of the protein, and the pellets were 
resuspended in the same amount of Urea 8M. Samples obtained were called “Solubilised IB”. 20 ul 
of each sample were added with 5ul of 5X Laemmli Buffer, heated at 100°C for 10’ and loaded on 
16% SDS-PAGE. 
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Recombinant protein purification 
Purification step was carried out using an immobilized metal ion affinity chromatography (IMAC) 
strategy. “Urea wash” was chosen as sample for the purification. ÄktaBasic chromatography system 
was used with an HisTrap FF 1 ml column (affinity column prepacked with precharged Ni 
Sepharose™ 6 Fast Flow, GE Healthcare). The purification protocol includes of the following steps: 
1. Column equilibration: wash the column with Binding Buffer until the ABS reaches a steady 
baseline (generally, at least 5 CV) 
2. Sample injection: using Superloop 
3. Column wash: wash the column with Binding Buffer until the ABS reaches a steady baseline 
(generally, at least 10 CV) 
4. Elution: wash the column with Elution Buffer. 
 
Binding Buffer pH 8 
Urea 8M 
NaH2PO4 100 mM 
Tris 10 mM 
NaCl 250 mM 
Imidazole 20 mM 
 
Elution Buffer pH 8 
NaH2PO4 100 mM 
Tris 10 mM 
NaCl 250 mM 
Imidazole 500 mM 
 
The presence of proteins in the different fractions (column flow, eluted fractions) was verified 
through 16% SDS-PAGE. 
 
Mass Spectrometry analyses of the purified fractions 
MALDI-MS analyses of the purified fractions were performed using two different matrixes: HCCA 
(MW range: 2-13 kDa) and sinapinic acid (5-20 kDa). Analyses were performed at Toscana 
Biomarkers srl, Siena. 
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hMOG35-117(His)6 cleavage trials with TEV 
In order to obtain the N-terminal free Cys on the recombinant protein, different buffer and 
incubation conditions with TEV enzyme were tested: 
1. Dilution of the protein to 1mg/ml with TEV Buffer 1. Cleavage reaction in TEV Buffer 1:  
a) @ RT for 3 h (100 ul of protein + 2 ul of TEV). 
b) @ 30°C for 3 h (100 ul of protein + 2 ul of TEV). 
c) @ 30°C for 24 h (100 ul of protein + 5 ul of TEV).  
d) @ 30°C for 24 h (100 ul of protein + 10 ul of TEV). 
e) @ 30°C for 48 h (100 ul of protein + 10 ul of TEV).  
Protein precipitation occurred in all the samples. 
2. Dilution of the protein to 1mg/ml with TEV Buffer 2. Cleavage reaction in TEV Buffer 2 @ 
30°C for 48 h (100 ul of protein + 10 ul of TEV), sample 4. Protein precipitation occurred. 
3. Dilution of the protein to 1 mg/ml with TEV Buffer 3. Cleavage reaction @30°C ON (100ul 
of protein + 5 ul TEV), sample 5. Protein precipitation occurred. 
4. Dilution of the protein to 1 mg/ml with TEV Buffer 4. Cleavage reaction:  
a) @30°C ON (120ul of protein + 12 ul TEV). 
b) @20°C ON (50ul of protein + 7 ul TEV). 
c)  Dilution of the protein to 1mg/ml with TEV Buffer 1. Cleavage reaction in TEV 
Buffer 1 @ 20°C ON (100 ul of protein + 10 ul of TEV). 
5. Dilution of the protein to 1 mg/ml with TEV Buffer 5. Cleavage reaction: 
a) @20°C ON (400 ul of protein + 40 ul TEV). 
b) @20°C ON (400 ul of protein + 40 ul TEV). Dialysis in buffer 1 @20°C for 24h. 
c) @20°C for 24h (400 ul of protein + 40 ul TEV). Dialysis in buffer 1 @20°C for 
24h. 
d) @20°C for 48h (400 ul of protein + 40 ul TEV). Dialysis in buffer 1 @20°C for 
24h. 
 
(TEVconsensus)-(Cys35)hMOG1-117(His)6 cleavage trials with TEV: MALDI-MS 
analyses 
Samples obtained after TEV cleavage reactions (both solutions and suspensions) were analyzed by 
MALDI-MS. All the analyses were performed at Toscana Biomarkers srl, Siena. Calculated masses 
of the two MOG form are the following:  
 (TEVconsensus)-(Cys35)hMOG1-117(His)6: 11,678 kDa 
 (Cys35)hMOG1-117(His)6: 10,752 kDa 
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(TEVconsensus)-(Cys35)hMOG1-117(His)6 cleavage trials with TEV: HPLC analyses 
HPLC analyses on (TEVconsensus)-(Cys35)hMOG1-117(His)6 
Analytical analyses were performed on a HPLC instrument coupled to ESI-MS using a C18 column. 
The viability of the test was verified using different methods on (TEVconsensus)-(Cys35)hMOG1-
117(His)6 protein sample, modifying the elution gradient in order to find the conditions allowing to 
obtain a single and well-separated peak containing the recombinant protein. The solvents used 
were: H2O with 0.1% TFA, ACN with 0.1% TFA. The selected method was from 30% ACN to 50% 
ACN in 5’ at a flow rate of 0.6 mL min-1. 
 
HPLC analyses on cleavage reaction samples  
Different incubation times were evaluated using the selected method on analytical HPLC. The 
protein was diluted to 1 mg/ml with buffer 5, then TEV was added (400 ul of protein + 40 ul TEV). 
The following cleavage reactions were performed: 
@20°C, ON. 
 
 
 
 
 
@20°C, 24h. 
 
 
 
 
 
@20°C, 41h. 
 
  
Chapter 2 
 
76 
hMOG35-117(His)6 cleavage trials with TEV: Buffers composition 
TEV Buffer 1, pH 7.5 
Tris 25 mM 
NaCl 250 mM 
ME 14 mM 
 
TEV Buffer 2, pH 7.5 
Tris 25 mM 
NaCl 250 mM 
ME 28 mM 
 
TEV Buffer 3, pH 7.5 
Tris 25 mM 
NaCl 250 mM 
TCEP 1 mM 
 
TEV buffer 4, pH 7.5 
NaH2PO4 100 mM 
Tris 10 mM 
NaCl 250 mM 
TCEP 1 mM 
 
TEV Buffer 5, pH 7.5 
Tris 25 mM 
NaCl 250 mM 
-mercaptoethanol 14 mM 
Urea 2 M 
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GENERIC METHODS 
Molecular Biology Generic Methods 
Sodium Dodecyl Sulphate PolyAcrilamide Gel Electrophoresis (SDS-
PAGE) 
Stacking gel and separating gel (in different percentages, according to the size of the proteins to be 
separated) were prepared as follows. Stacking gel was poured on top of the separating gel after 
solidification (30’ at RT). Gel comb was inserted into the stacking gel, in order to allow the 
formation of the wells. Protein samples were diluted with 5X Laemmli Buffer and boiled at 100°C 
for 10’. 15 ul of each sample were loaded into a well. When all the samples were loaded, the 
apparatus was filled with Tris-SDS Running Buffer (250 mM Tris, 1.92 M Glycine, 1% SDS, pH 8.3), 
then a voltage of 150 V was applied for 1h. After the run, the gel was incubated with Staining 
Solution (0.1% Coomassie R250, 10% acetic acid, 40% methanol) or 1h at RT. Nonspecific bands 
were removed washing and the gel twice with Destaining Solution (10% acetic acid, 40% methanol) 
(1h incubation each). 
 
Separating Gel, 18% - 8 ml 
Reagent Volume  
dd H2O 1 ml 
30% Acrylamide 4,8 ml 
1.5M Tris pH 8.8 2 ml 
10% SDS 80 ul 
10% APS 80 ul 
Temed 8 ul 
 
Separating Gel, 16% - 8 ml 
Reagent Volume  
ddH2O 1,6 ml 
30% Acrylamide 4,27 ml 
1.5M Tris pH 8.8 2 ml 
10% SDS 80 ul 
10% APS 80 ul 
Temed 8 ul 
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Stacking Gel, 4% - 3 ml 
Reagent Volume  
ddH2O 1,8 ml 
30% Acrylamide 400 ul 
0.5M Tris pH 6.8 750 ul 
10% SDS 30 ul 
10% APS 30 ul 
Temed 3 ul 
 
Tricine-PAGE 
Stacking gel and separating gel were prepared as follows: 
Separating Gel, 18% - 8 ml 
Reagent Volume  
ddH2O 880 ul 
30% Acrylamide 2,7 ml 
3 M Tris pH 8,45 2 ml 
Ethylene glycole 2,4 ml 
10% APS 32 ul 
Temed 12 ul 
 
Stacking Gel, 5% - 4 ml 
Reagent Volume  
ddH2O 2,62 ml 
30% Acrylamide 375 ul 
3 M Tris pH 8,45 1 ml 
10% APS 16 ul 
Temed 16 ul 
 
Protein samples were diluted with 5X Laemmli Buffer (60 mM Tris-Cl pH 6.8, 2% SDS, 10% 
glycerol, 5% β-mercaptoethanol, 0.01% bromophenol blue) and boiled at 100°C for 10’. 15 ul of each 
sample were loaded into a well. When all the samples were loaded, the apparatus was filled with 
Tris-SDS Running Buffer, then a voltage of 200 V was applied for 1h. After the run, the gel was 
stained as reported for SDS-PAGE. 
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Agarose gel 
According to the size of the DNA fragment to be separated, different Agarose percentages were 
selected to prepare the gel. 
Recommended % Agarose Optimum Resolution for Linear DNA 
0.5 1,000–30,000bp 
0.7 800–12,000bp 
1.0 500–10,000bp 
1.2 400–7,000bp 
1.5 200–3,000bp 
2.0 50–2,000bp 
 
E.g., to prepare 30 ml of 1% agarose gel, 3 g of agarose powder were dissolved in 30 ml Tris-Acetate-
EDTA Buffer, TAE (40 mM Tris, 20 mM acetic acid and 1 mM EDTA) under heating. The solution 
was cooled, then 3 ul of Sybr Safe were added and the mixture was poured into the instrument. Gel 
comb was inserted, and the gel was allowed to polymerize at RT for 1 h, then the apparatus was 
filled with TAE Buffer. Each DNA samples was diluted with 6X Loading Buffer and loaded into a 
well, then a voltage of 180V was applied for 1h. The presence of bands was revealed using an UV 
transilluminator. 
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PRIMARY BILIARY CIRRHOSIS 
Primary Biliary Cirrhosis (PBC) is an immune-mediated chronic inflammatory liver disease with 
slow progression. PBC is characterized by destruction of small interlobular bile ducts, gradual 
cholestasis and portal inflammation. Loss of bile ducts causes both decrease of bile secretion and 
retention of toxicants within the liver, resulting in fibrosis, cirrhosis and, ultimately, need for a liver 
transplantation133. Enhanced awareness in the diagnostic field, together with an increased 
knowledge of PBC pathogenesis, lead to most frequent and early diagnoses. Indeed, more than half 
of the diagnosed pts is asymptomatic134. The diagnosis can be established when two of the following 
criteria are met: biochemical evidence of cholestasis based on alkaline phosphatase elevation; 
presence of serum anti-mitochondrial Ab (AMA) of the IgG class by indirect immunofluorescence 
(IIF); histological evidence of non-suppurative destructive cholangitis and destruction of 
interlobular bile ducts on bioptic tissue135. 
PBC etiology can be defined multifactorial, as it was widely hypothesized that the disease is 
triggered by environmental exposure in the context of a genetic background permissible for 
autoimmunity development136. Indeed, variation in geographical prevalence, presence of disease 
clustering, and seasonal differences in disease diagnosis provide evidence for a crucial 
environmental role in PBC development. Evidence for the strong impact of genetic factors is 
provided by the overlap with other AID137, the high monozygotic twin concordance (about 60%)6,138, 
and the increased sibling risk of AMA positivity139 and PBC development140. Furthermore, GWAS 
identified independent association with genes of known immunological function141–143. To note, 
many of the PBC-associated loci overlap with signals obtained for other AID, suggesting that these 
genetic differences may be linked to autoimmunity. Although genetic factors play an important role 
in the development of complex autoimmune disease, it is becoming apparent that environmental 
exposures are equally important. Indeed, progression and disease severity are variable among 
affected monozygotic twins, and the concordance between dizygotic twins is nearly 0%136. It is 
reasonable to hypothesize that environmental factors may ultimately induce tolerance breakdown 
through a variety of mechanisms in genetically susceptible individuals. Effectively, xenobiotics 
contribution to PBC pathogenesis may be due to potential direct cellular effect (leading to apoptosis 
or oncosis), and/or chemical modification of native proteins, causing neo-Ag formation, while 
viruses or bacteria may evoke a molecular mimicry mechanism. For example, several peptides and 
proteins from bacteria commonly associated with PBC (including E. coli, Novosphingobium 
aromaticivorans, and Lactobacillus delbrueckii) were shown to strongly cross-react with AMA and 
activate T-cell clones from PBC patients144–146, disclosing how PBC could be due to exposure to 
bacterial Ag. 
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PBC immunopathogenesis: the key role of anti-mitochondrial 
Ab 
Even if factors leading to PBC remain poorly understood, the disease is considered a model 
AID147,148. Indeed, the high specificity of the bile ducts damage is a unique and critical feature of 
PBC, and suggests the occurrence of an intense autoimmune response directed against biliary 
epithelial cells. This hypothesis is supported by the presence of MHC class II Ag on the biliary 
epithelium and lymphoid infiltration in the portal tract148. Furthermore, PBC has a serological 
hallmark signature, represented by AMA, highly disease-specific auto-Ab found in 90-95% of pts 
and less than 1% of healthy controls149.  
Numerous studies aimed to understand the molecular immunopathogenic mechanisms underlying 
the disease were performed since the 50s, when a PBC serum was found to react with tissue extracts 
by complement fixation150. In 1965 the reactant was located to mitochondria by IIF and called 
M2151. The first attempts of M2 molecular characterization were achieved 20 years later by 
Gershwin et al., which identified the reactant with a family of proteins of 48-74 kDa by both 
immunoblotting and molecular cloning149, and Yeaman et al., which showed that M2 is the E2 
component of the mammalian pyruvate dehydrogenase complex152. Subsequently, both Van de 
Water et al. and Coppel et al. confirmed that M2 is represented by multiple subunits of the 2-0x0-
acid dehydrogenase complex153,154, which is located in the inner mitochondrial membrane and is 
responsible of the oxidative decarboxylation of keto-acid substrates155. In particular, the targets of 
AMA are represented by:  
 dihydrolipoamide acetyltransferase (E2 component of the pyruvate dehydrogenase 
complex, PDC-E2), which is the most frequently detected;  
 dehydrogenase dihydrolipoyl transacylase (E2 subunit of the branched-chain 2-oxo-acid 
dehydrogenase, BCKD-E2);  
 dihydrolipoamide succinyltransferase (E2 component of the oxo-glutarate dehydrogenase 
complex, OGDC-E2);  
 dihydrolipoamide dehydrogenase binding protein or E3-binding protein (E3-BP)147.  
It is important to note that AMA auto-Ag share a substantial homology, having a common highly-
conserved N-terminal domain containing a lipoylated Lys residue (Figure 37)148.  
 
Figure 37: Lipoyl domain homology of mitochondrial auto-Ag 
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The specifically localized damage at the intrahepatic bile ducts and the ubiquitous auto-Ag 
expression lead to the PBC paradox149. In order to explain this phenomenon, it was hypothesized 
that the peculiar biliary epithelial cells metabolic processing of AMA Ag during apoptosis may 
attract the immune response on bile-duct cells (Figure 38). In particular, three observations on the 
PDC-E2 Ag demonstrate the importance of these differences in understanding PBC 
immunopathogenesis: 
1. PDC-E2 can be recognized by auto-Ab depending on the attachment of glutathione to the 
lipoylated Lys during apoptosis156; 
2. differently from other cell types, epithelial cells do not attach glutathione to PDC-E2 lipoyl-
Lys group during apoptosis157; 
3. specific modifications of the inner lipoyl domain of the PDC-E2 have shown to be 
immunoreactive when tested with pts serum, suggesting the importance of lipoyl-Lys 
moiety status158. 
Studies on cultured human intrahepatic biliary epithelium cells (HIBEC) confirmed that the 
autoimmune injury in PBC is a consequence of the unique characteristics of HIBEC during 
apoptosis159, and subsequently it was demonstrated that biliary apotopes and AMA are able to 
activate innate immune responses in mature monocyte-derived macrophages cultures160. These 
findings provide further evidences to the hypothesis of a specific apoptotic mechanism responsible 
for the strictly localized PBC autoimmune response. 
 
Figure 38: Properties of Apoptosis in Somatic Cells and Biliary Epithelial Cells148. 
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Although it is widely demonstrated that PDC-E2 is main target of AMA, the definition of its 
immunodominant epitope is still controversial (as shown in Table 5). PDC-E2 was originally 
mapped digesting the corresponding cDNA clone with restriction endonucleases and subcloning 
the obtained fragments into frame-shifted expression vectors. The clone encoding for the main 
immunogenic region was identified by immunoblot assays with PBC pts sera. Subsequently, to 
precisely define the epitope, peptides encompassing distinct hydrophilic peaks within this region 
were synthesized and tested by ELISA, leading to the identification of the immunodominant 
epitope the highly conserved Aa surrounding the lipoyl-Lys residue in position 173 (K173), and in 
particular to the 20 Aa linear peptide AEIETDKATIGFEVQEEGYL corresponding to Aa 167-186 
within hPDC-E2153. The putative relevance of lipoic cofactor was further disclosed in another study, 
which reported the presence of a minor epitope 
associated with the outer lipoyl domain (Aa 1-80)161 (    
Figure 39). Lipoyl domains are fundamental for PCD-
E2 function in pyruvic acid metabolism, acting as 
acceptor of acetyl groups formed by the oxidative 
decarboxylation of pyruvate and transferring them to 
coenzyme A (Figure 40). Even though the previously 
mentioned studies represent the basis for the 
hypothesis of an involvement of lipoic acid in the AMA 
Ab recognition, it is important to stress that they have 
not taken into account the lipoylation status of the 
employed Ag. 
    Figure 39: Aa sequence of PDC-E2 162. 
 
 
Figure 40: On the left, 3D image of PDC complex, showing the subunit structure: E1, pyruvate 
dehydrogenase; E2, dihydrolipoyl transacetylase; and E3,dihydrolipoyl dehydrogenase. The core 
(green) consists of 60 molecules of E2, arranged in 20 trimers to form a pentagonal 
dodecahedron. The lipoyl domain of E2 (blue) reaches outward to touch the active sites of E1 
molecules (yellow) arranged on the E2 core. A number of E3 subunits (red) are also bound to the 
core, where the swinging arm on E2 can reach their active sites. An asterisk marks the site where 
a lipoyl group is attached to the lipoyl domain of E2. On the right, the oxidative decarboxylation of 
pyruvate to acetyl-CoA by the PDC complex. 
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The identification of the main immunogenic region with hPDC-E2(167-186) was questioned by 
Braun et al.162. In this work, 33 synthetic overlapping peptides covering the entire length of PDC-
E2 were tested by SP-ELISA. The authors showed that the reactivity of PBC sera with peptides 
containing the immunodominant epitope in both inner and outer lipoyl domain was rather low, 
although significantly higher than that of NBD. In contrast, up to 74% of the PBC sera reacted with 
the two peptides within the catalytic domain (Aa 407-431 and 475-499) and the peptide 101-125 in 
the first hinge region. Sera from AMA- PBC pts hardly reacted with any of the peptides. In addition, 
they evaluated the function of lipoic acid synthesizing the immunodominant peptide 167-184 in 
both unlipoylated and lipoylated form. In order to find out whether Ab may recognize a 
conformational epitope, either peptide was also coupled with ovalbumin (OVA). For this purpose, 
it was necessary to add a Cys at the C-terminal end, which had to be substituted by a Lys for coupling 
the LA-conjugated. Compared with the unconjugated analogues, the OVA conjugates exhibited 
stronger reactivity. However, most sera showed high reactivity also with OVA alone, disclosing a 
huge limitation of this study. After subtracting the reactivity to OVA alone from the OVA-coupled 
peptides, 44% of PBC sera had IgG response to the unlipoylated (OVA-167-184) peptide and 22% 
to the lipoylated peptide (OVA-167-184-LA). IgM were found in 57% and 31%, respectively. 
Therefore, the higher Ab response was detected by the unlipoylated peptide (Figure 41). 
 
Figure 41: Data distribution of IgG (left) and IgM (right) reactivity of PBC sera  
with OVA-167-184, OVA-167-184-LA and OVA alone.  
 
  
Role of PTM in Primary Biliary Cirrhosis 
 
87 
Significance of lipoic acid cofactor in Ab recognition 
The identification of the main immunogenic region with the inner lipoyl domain of PDC-E2 
prompted the investigation on the role of lipoic acid cofactor. From a conformational point of view, 
a study on Bacillus stearothermophylus PCD-E2 lipoyl domain disclosed that lipoylation does not 
impose any conformational change on the secondary structure of the protein163. If the same 
condition occurs in the human analog, this would imply that the Ab recognition of the lipoylated 
form is not a consequence of any conformational change imposed by the lipoate attachment, but 
involves the lipoate group per se164. The resolution of the 3D structure of lipoylated recombinant 
hPDC-E2132-208 by Howard et al. revealed that the inner lipoyl domain is characterized by a β-barrel 
containing two antiparallel β-sheet, each of which contains three major strands and one minor 
strand. Intriguingly, they hypothesized that the lipoylated K173 is prominently exposed at the top of 
a tight type I β-turn (Figure 42)165, but without verifying the lipoylation status of the recombinant 
protein. This serious issue represents a crucial limitation of this study for two reasons. Firstly, the 
3D structure obtained in this study may not represent the native one. Secondly, although they 
documented the K173 localization on the tip of the -turn, the prominent exposition of lipoic acid is 
not demonstrated, as the presence of lipoylation may affect both conformation and folding of the 
domain, resulting in a different 3D structure. 
 
 
 
 
 
 
 
Figure 42: Representation of recombinant  
hPDC-E2132-208 polypeptide fold hypothesized by Howard.  
Lipoylation site is indicated together with the type I β turn 
(black). The β sheet containing K173 residue is shown in dark 
grey; β sheet containing N- and C-terminal residues is shown 
in light grey. 
 
 
 
Since the main immunogenic region of PCD-E2 was identified with the inner lipoyl domain of the 
protein, the involvement of lipoyc acid in the IgG auto-Ab response was intensely examined. 
Unfortunately, the use of inhomogeneous and not well characterized Ag preparations led to an 
intricate situation. Indeed, these studies employed PDC-E2 of different origin (bacterial, human, 
rat), using the whole protein or a sub-domain, obtained by extraction or produced by molecular 
biology, and even short peptide fragments, prepared by chemical synthesis and, in one case, 
conjugated to an irrelevant proteins (such as OVA), to mimic the native Ag. Therefore, a univocal 
conclusion was not reached yet, as outlined by some of the most remarkable studies summarized 
in Table 5, and the role of lipoic acid in PBC autoimmunity is still matter of debate.  
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Authors  
(year) 
Ag description Lipoate attachment 
is required for Ab 
recognition? 
Gershiwn et al. 
(1987)149 
Fused polypeptide (obtained by screening of rat liver cDNA 
library) expressed in E.coli. 
Lipoylation status was 
not taken into account 
during the Ag 
characterization. 
Van de Water 
et al.  
(1988)153 
Synthetic peptides of rPDC-E2 (mapping of the fused 
polypeptide obtained by Gershwin149). 
Lipoylation status was 
not taken into account 
during the Ag 
characterization. 
Coppel et al. 
(1988)154 
Recombinant hPDC-E2 of unknown lipoylation state 
expressed in E.coli. 
Lipoylation status was 
not taken into account 
during the Ag 
characterization. 
Mutimer et al. 
(1989)166 
Extractive PDC-E2 from bovine heart. Lipoylation status was 
not taken into account 
during the Ag 
characterization. 
Fussey et al.  
(1990)161 
Lipoylated, unlipoylated and octanoylated PDC-E2 extracted 
from E.coli  
Yes  
(also octanoylated 
protein detects Ab) 
Leung et al.  
(1990)167 
Recombinant hPDC-E2 of unknown lipoylation state. Ag was 
engineered by site directed mutagenesis, substituting K173 to 
make new unlipoylatable isoforms, which are as immunogenic 
as the wild type.  
No 
Tuaillon et al.  
(1992)168 
Lipoylated and unlipoylated synthetic octadecapeptides 
conjugated with OVA. Racemic lipoic acid is directly coupled 
to the side chain of Lys. 
Yes 
 
Quinn et al.  
(1993)164 
Lipoylated and unlipoylated recombinant hPDC-E2 inner 
lipoyl domain expressed in E.coli. Lipoylation was performed 
in vitro using racemic mixture. 
Yes 
 
Koike et al. 
(1998)169 
PDC-E2 from porcine heart, enzimatically delipoylated and 
re-lipoylated.  
No 
Bruggraber, et 
al. 
(2003)157 
 Free lipoic acid  
 Recombinant lipoylated hPDC-E2 
 PDC-E2 unrelated carrier bound lipoate. 
 
Yes 
(Reactivity is specific 
for conjugated form 
of lipoyc acid, 
irrespective of the 
protein carrier) 
Braun, et al. 
(2010)162 
 Lipoylated and unlipoylated synthetic hPDC-E2(167-184) 
 Lipoylated and unlipoylated synthetic hPDC-E2(167-184) 
conjugated with OVA. 
No 
 
Table 5: Summary of the literature on lipoic acid involvement in PBC autoimmunity. 
  
Role of PTM in Primary Biliary Cirrhosis 
 
89 
According to the popular assumption of xenobiotics as trigger for PBC, it was hypothesized that the 
exposure to certain compounds may cause aberrant modifications on lipoic acid, leading to neo-
epitope uncovering. The susceptibility of lipoic acid to non-natural alteration may be explained 
considering its prominent exposition on the outer surface of the protein165. Furthermore, lipoic acid 
is able to rotate with respect to the PDC-E2 molecule by means of its “swinging arm”, allowing the 
accessibility of its dithiolane ring for reductive acylation170,171. This conformational change, together 
with the existence of multiple conformations of lipoyl domain during the reductive acylation170, is 
required for acyl transfer mechanism, but renders the cofactor vulnerable to modifications. Indeed, 
it was shown that PDC-E2 conjugated to some synthetic small molecules able to mimic lipoic acid 
displays highly specific reactivity to AMA+ PBC sera, at levels often higher than the native 
molecule172,173. In this context, one of the most relevant work is that of Amano et al.174, which 
concerns the replacement of lipoic acid on synthetic PDC-E2(169-183) by 107 different xenobiotics. 
They showed that 33/107 xenobiotics have significantly higher IgG reactivity against PBC sera 
compared with NBD, and one of the compounds, 2-octinoyc acid (Figure 43), is more reactive than 
the native lipoylated peptide. Interestingly, the methyl ester of this molecule is one of the oldest 
artificial flavoring and was widely used since the 1900s in perfumed cosmetics for its violet scent. 
Other relevant findings were achieved by Leung et al.175, which addressed the question whether the 
physiological lipoyl ring reduction renders the lipoyc acid receptive for xenobiotics modification, 
testing synthetic thioesters modified analogs of open-ring lipoyc acid. They verified that three of 
these molecules, namely 6,8-bis(acetylthio)octanoic acid (SAc), 8-(acetylthio)octanoic acid and 
6,8-bis(propionylthio)octanoic acid (Figure 43), showed highly reactivity to AMA+ sera compared 
to the native lipoylated protein. These data suggest that xenobiotics alterations of the lipoyl S-S 
linkage during physiological electron transfer could break immunological tolerance to PDC-E2, 
according to the former hypothesis that the oxidative state of PDC-E2 may affect its 
immunogenicity156. In the same study it was demonstrated that purified anti-SAc-bovine serum 
albumin (BSA) conjugate Ab are of the IgM type, and are able to recognize both SAc-BSA and 
recombinant PDC-E2, while purified anti-recombinant PDC-E2 Ab are of the IgG type and 
recognize only PDC-E2. Based on these results, the presence of the following process may be 
argued: 
1. The initial exposure to chemicals leads to a primary IgM specific immune response against 
the exogenous Ag;  
2. Subsequently, the similarity between the lipoyl domain of PDC-E2 and the xenobiotic 
generates a cross-reactive response to the self-Ag, causing self-tolerance breakdown to the 
native protein;  
3. In the end, the affinity maturation and isotype switching processes lead to a secondary IgG 
immune response to the native protein176. 
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Figure 43: Chemical structure of lipoic acid (LA) and related xenobiotc compounds.  
SAc = 6,8-bis(acetylthio)octanoic acid; 2OA = 2-octinoyc acid;  
SCOEt = 6,8-bis(propionylthio)octanoic acid;  
OASAc=8(acetylthio)octanoic acid. 
 
In a few words, the hypothesis of lipoic acid as minimal epitope candidate in the case of PBC was 
deeply investigated, but remains highly controversial. The assumption of a role of lipoic acid in PBC 
immunopathogenesis is supported by both cofactor localization165 and oxidized state during 
pyruvate decarboxylation170, which make it an easy target for auto-Ab and aberrant chemical 
modifications due to xenobiotic exposure. However, the presence of inhomogeneous data on this 
topic led to a confusing situation that needs further clarifications. 
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AIM OF THE WORK 
PBC is a chronic liver AID characterized by the presence of highly specific serum AMA in 95% of 
pts. The current diagnostic tool for AMA detection is based on IIF detection of serum IgG targeting 
the so-called M2 Ag, which is represented by a pool of various, not fully characterized Ag. Indeed, 
AMA test is performed using whole tissues from rat kidney as Ag substrate, enabling the detection 
on a heterogeneous Ab population directed against an undefined complex set of proteins. This 
unclear situation may be resolved through a precise molecular definition of the immunodominant 
epitope(s), which may provide critical insights into the molecular basis of PBC immunology and 
ethiopathogenesis. The main immunogenic region of AMA was mapped to the inner lipoyl domain 
of PDC-E2, and in particular to the Aa residues surrounding the lipoylated K173 of the linear peptide 
AEIETDKATIGFEVQEEG, corresponding to PDC-E2(167-184)153. The importance of the lipoyl-Lys 
seems to be confirmed by its relevant localization within the protein, on the tip of a type I -turn165. 
It was also speculated that the lipoic acid itself is prominently exposed on the -turn, but since the 
structural studies were performed without verifying the lipoylation status of the analyzed protein 
this is only one of the possible hypothesis. In addition to the doubts of its structural localization, to 
date also the role of lipoic acid per se and of the lipoylation on the immunodominant peptide is still 
debated for several reasons. First, different Ag preparations, including peptides, recombinants and 
conjugated molecules, were use. Second, the length and origin (bacterial, human, rat) of the PDC-
E2 sequences employed is extremely heterogeneous. Third, the assays used for anti-PDC-E2 
detection range from immunoblot to IIF. Last but not least, some studies have not taken into 
account the lipoylation status of the probes. 
In this scenario, we decided to characterize the PDC-E2 immunodominat region (Aa 167-184) from 
a molecular point of view. We focused our attention on both lipoylation and aberrant PTM that may 
occur on this region, using well-characterized synthetic peptide probes resulting from the human 
sequence. These peptides were used as antigenic probes in SP-ELISA to detect Ab in PBC pts sera.  
The project addressed the following issues: 
1. Role of lipoic acid and its chiral center 
Lipoic acid is an essential cofactor of many enzyme complex, and its role is crucial in aerobic 
metabolism. As the C6 of the molecule is chiral, lipoic acid exists as two enantiomers, (R)-lipoic 
acid and (S)-lipoic acid (Figure 44), and as a racemic mixture (R/S)-lipoic acid. Only the (R)-
enantiomer exists in nature. To date, the role of the two enantiomers and/or the racemic 
mixture in PBC immunopathogenesis was not taken into account. For this purpose, we 
developed a SPPS strategy aimed to introduce both the natural and non-natural enantiomers 
of lipoic acid on the immunodominant epitope in a controlled fashion. Using this methodology, 
we synthesized and characterized [(R)-Lipoamide-Lys173]PDC-E2(167-186)-KKKK and [(S)-
Lipoamide-Lys173]PDC-E2(167-186)-KKKK. To elucidate the significance of lipoic acid, the 
unlipoylated form of the peptide was also synthesized: [Lys173]PDC-E2(167-186)-KKKK. In 
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order to enhance the solubility of PDC-E2(167-186) derived peptides, and to allow the coating 
on the ELISA plate, a 4-Lys tag (KKKK) was added to the C terminus of all the PDC-E2(167-
186) peptides. 
 
Figure 44: (R)-lipoic acid (top) and (S)-lipoic acid (down) 
 
2. Role of K173 lipoylation and relevance of K173 hypothetical exposition on the tip of the β-turn 
In order to clarify the role of the presence of lipoyl-modified Lys residue on the 
immunodominant sequence, and the importance of its presumed exposition on the β-turn in 
the Ab recognition, we inserted the lipoylated Lys on the tip of a scaffold β-turn peptide 
sequence. We selected the 21-mer peptide CSF114, as we previously demonstrated its ability to 
expose optimally post-translationally modified residues on the tip of a type I’ β-turn 
(corresponding to position 7) as irrelevant peptide sequence177. Analogues of CSF114 bearing 
the same PTM of hPDC-E2 peptides were designed: [(R)-Lipoamide-Lys7]CSF114, [(S)-
Lipoamide-Lys7]CSF114 and [Lys7]CSF114. 
 
3. Relevance of N-glucosylation in PBC autoimmunity 
The involvement of aberrant N-glucosylation in autoimmunity and the role of Asn(Glc) as 
minimal epitope exposed on a type I’ β-turn structure was previously demonstrated36,37. In 
order to assess a possible role of glucosylation in PBC autoimmunity, we synthesized an analog 
of PDC-E2 peptide containing the minimal epitope Asn(Glc) exposed on the tip of the β-turn 
(same position of the natural lipoylated Lys): [Asn173(Glc)]PDC-E2(167-186)-KKKK. The 
specificity of the response against Glc was evaluated synthesizing also the peptide bearing an 
N-acetyl-glucosamine (GlcNAc) on Asn residue: [Asn173(GlcNAc)]PDC-E2(167-186)-KKKK. To 
further clarify the relevance of glucosylation, the corresponding unglucosylated peptide (with 
the Lys → Asn mutation) was synthesized: [Asn173]PDC-E2(167-186)-KKKK. Finally, we 
investigated a possible role of Asn(Glc) independently from the specific sequence of PDC-E2, 
we prepared and tested analogues of CSF114 with the same PTM of hPDC-E2 peptides: 
[Asn7(Glc)]CSF114, [Asn7(GlcNAc)]CSF114 and [Asn7]CSF114 . 
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Further to the molecular characterization of the PDC-E2 immunodominant region, we evaluated 
the possible diagnostic relevance of the previously mentioned peptides (summarized in Table 6). 
For this purpose, we tested the synthetic probes as Ag in SP-ELISA, comparing the results obtained 
in the PBC cohort with other control diseases, such as Rheumatoid Arthritis (RA) and Scleroderma 
(SSC), and NBD. 
 
PDC-E2 series CSF114 Series 
[(R)-Lipoamide-Lys173]PDC-E2(167-186)-KKKK [(R)-Lipoamide-Lys7]CSF114 
[(S)-Lipoamide-Lys173]PDC-E2(167-186)-KKKK [(S)-Lipoamide-Lys7]CSF114 
[Lys173]PDC-E2(167-186)-KKKK [Lys7]CSF114 
[Asn173(Glc)]PDC-E2(167-186)-KKKK [Asn7(Glc)]CSF114 
[Asn173(GlcNAc)]PDC-E2(167-186)-KKKK [Asn7(GlcNAc)]CSF114 
[Asn173]PDC-E2(167-186)-KKKK [Asn7]CSF114 
  
Table 6: Summary of the peptides used in the PBC study §.  
All the peptides were synthesized by SPPS at the SOSCO Laboratory  
(Universitè de Cergy Pontoise, France).  
                                                          
§ Rentier, C., Pacini, G., Nuti, F., Peroni, E., Rovero, P., Papini, A. M.,Synthesis of diastereomerically 
pure Lys(N-lipoyl) building-blocks and their use in Fmoc/tBu solid phase synthesis of lipoyl-
containing peptides for diagnosis of paciprimary biliary cirrhosis. Journal of Peptide Sciences, 
submitted. 
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RESULTS & DISCUSSION 
Importance of lipoyc acid and its chiral center 
[(R)-Lipoamide-Lys173]PDC-E2(167-186)-KKKK, [(S)-Lipoamide-Lys173]PDC-E2(167-186)-KKKK 
and [Lys173]PDC-E2(167-186)-KKKK were tested for both IgG and IgM on a cohort of 65 PBC pts 
using SP-ELISA. IgM on [(S)-Lipoamide-Lys173]PDC-E2(167-186)-KKKK were tested on a smaller 
cohort. 
Results obtained display an Ab response against all the peptides tested (Figure 45). In particular, a 
paired t test confirmed that values obtained for the (R)- and (S)-enantiomers are comparable (P= 
0.499 in the case of IgG and P= 0.367 for IgM), allowing us to assume that the lipoic acid chirality 
on the C6 has no influence on the Ab recognition.  
The presence of a response against [Lys173]PDC-E2(167-186)-KKKK enables to hypothesize that a 
PTM (namely, a de-lipoylation) can uncover a neo-epitope. 
 
 
Figure 45: IgG (left) and IgM (right) data distribution of PBC sera against  
[Lys173]PDC-E2(167-186)-KKKK, [(S)-Lipoamide-Lys173]PDC-E2(167-186)-KKKK and  
[(R)-Lipoamide-Lys173]PDC-E2(167-186)-KKKK. P-values obtained in paired t tests are shown. 
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Role of lipoyl-K173 and the relevance of K173 exposition on the tip 
of the β-turn 
Results obtained with [(R)-Lipoamide-Lys173]PDC-E2(167-186)-KKKK, [(S)-Lipoamide-
Lys173]PDC-E2(167-186)-KKKK and [Lys173]PDC-E2(167-186)-KKKK were compared with the one 
achieved with CSF114 corresponding analogues: [(R)-Lipoamide-Lys7]CSF114, [(S)-Lipoamide-
Lys7]CSF114 and [Lys7]CSF114. All the peptides were tested for both IgG and IgM on a cohort of 
65 PBC pts using SP-ELISA. IgM on [(S)-Lipoamide-Lys173]PDC-E2(167-186)-KKKK were tested 
on a smaller cohort. 
A paired t test confirmed that the absorbance values observed against CSF114 series are lower than 
the one obtained with the corresponding PDC-E2 analogues (Figure 46). These findings enable us 
to speculate that K173 (both lipoylated and unlipoylated) exposed on the type I’ β-turn irrelevant 
peptide sequence is not able to detect Ab in PBC pts, and therefore that the Aa residues surrounding 
the lipoyl-Lysine are required for Ab recognition. 
 
 
Figure 46: IgG (left) and IgM (right) data distribution of PBC sera against  
[Lys173]PDC-E2(167-186)-KKKK, [Lys7]CSF114,  
[(S)-Lipoamide-Lys173]PDC-E2(167-186)-KKKK, [(S)-Lipoamide-Lys7]CSF114,  
[(R)-Lipoamide-Lys173]PDC-E2(167-186)-KKKK and [(R)-Lipoamide-Lys7]CSF114.  
P-values obtained in paired t tests are shown: **** P < 0,0001. 
 
  
Chapter 3 
 
96 
Relevance of N-glucosylation in PBC autoimmunity 
[Asn173(Glc)]PDC-E2(167-186)-KKKK, [Asn173]PDC-E2(167-186)-KKKK, [Asn7(Glc)]CSF114 and 
[Asn7]CSF114 were tested for both IgG and IgM on a cohort of 65 PBC pts using SP-ELISA.  
Results obtained (Figure 47) display a high and specific response in the case of [Asn173(Glc)]PDC-
E2(167-186)-KKKK, uncovering the hypothesis of an involvement of aberrant N-glucosylation in 
the immunopathogenesis of PBC.  
To verify the specificity of the Ab response detected against glucose, [Asn173(GlcNAc)]PDC-E2(167-
186)-KKKK and [Asn173(GlcNAc)]CSF114 were tested on a smaller cohort of sera (n=7).  
Results obtained show that the higher titers detected in both CSF114 and PDC-E2 series concerns 
[Asn(Glc)] peptides (Figure 48). We can assume that the response is [Asn(Glc)]-specific, as 
[Asn(GlcNAc)] peptides are unable to recognize Ab in PBC pts sera. It is important to note that 
[Asn173(Glc)]PDC-E2(167-186)-KKKK could also mimic a different self Ag bearing an aberrant N-
glucosylation. For this purpose, further investigations on the involvement of N-glucosylation in 
PBC are required, such as the characterization of anti-[Asn173(Glc)]PDC-E2(167-186)-KKKK Ab 
isolated from pts sera and the assessment of the cross-reactivity between these Ab and the other 
PDC-E2 antigenic probes. 
 
Figure 47: IgG (left) and IgM (right) data distribution of PBC sera against  
[Asn173]PDC-E2(167-186)-KKKK, [Asn7]CSF114,  
[Asn173(Glc)]PDC-E2(167-186)-KKKK and [Asn7(Glc)]CSF114. 
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Figure 48: Comparison between [Asn], [Asn(Glc)] and [Asn(GlcNAc)] results  
for both IgG (left) and IgM (right). 
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Search of an antigenic probe able to recognize disease-specific 
auto-Ab in PBC pts sera 
The antigenic probes summarized in Table 6 were tested as antigenic probes in SP-ELISA, in order 
to identify auto-Ab in pts sera as disease BM. Disease-specificity of the detected Ab was evaluated 
comparing the results obtained in PBC pts with NBD cohort using a cutoff value calculated as (mean 
value of NBD) + 3*(standard deviation of NBD). Data distribution of all the tests are shown in 
Supplementary Data.  
Unpaired t tests with Welch’s correction confirmed that the difference between the results obtained 
for PBC pts and for NBD are statistically significant for all the Ag. Furthermore, we included 3 
different cohorts of disorders as pathological control groups: RA, SSC and other not-hepatic AID 
(OAID). The most interesting results were achieved using the PDC-E2 peptide series (Figure 49). 
Comparing PBC data with NBD through cutoff value allowed us to identify [Lys173]PDC-E2(167-
186)-KKKK as the most relevant antigenic probe for IgM detection. This peptide is able to recognize 
63% of PBC pts, even if with lower titers compared with the lipoylated peptide [(R)-Lipoamide-
Lys173]PDC-E2(167-186)-KKKK, which is able to discriminate 37% of pts (Figure 50). PBC-
specificity of the detected Ab was confirmed using 3 different pathologic control cohorts: RA 
(n=22), SSC (n=12) and OAID (n=47). In particular, we obtained 0% positivity percentage for IgM 
against the unlipoylated PDC-E2 peptide in both RA and SSC cohorts, while OAID have 23% of 
positivity (Figure 51). This finding enabled us to hypothesize that [Lys173]PDC-E2(167-186)-KKKK 
may represent the target of auto-Ab response in the case of PBC. The disease specificity of detected 
Ab is confirmed by the comparison with all the three pathological control cohorts. Such a result is 
remarkable, as RA is characterized by high levels of circulating auto-Ab, in particular rheumatoid 
factors, cross-reactive Ab that may cause interference in solid phase assays. SSC was selected as 
control disease because it is often associated with PBC, suggesting a common genetic background 
for the two disorders. SSC sera included in this study, however, are AMA negative and contain auto-
Ab of other specificities, not reactive with the PDC-E2 sequences. 
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Figure 49: IgG (left) and IgM (right) data distribution of PBC sera against  
[Lys173]PDC-E2(167-186)-KKKK, [(R)-Lipoamide-Lys173]PDC-E2(167-186)-KKKK,  
[Asn173]PDC-E2(167-186)-KKKK and [Asn173(Glc)]PDC-E2(167-186)-KKKK 
 
 
 
Figure 50: IgM data distribution of PBC pts and NBD against  
[Lys173]PDC-E2(167-186)-KKKK (left), and  
[(R)-Lipoamide-Lys173]PDC-E2(167-186)-KKKK (right).  
Dotted line indicate the cutoff value. 
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Figure 51: IgM data distribution of PBC pts against [Lys173]PDC-E2(167-186)-KKKK  
compared with control cohorts: NBD, RA, SSC and OAID.  
Dotted line indicate the cutoff value.  
P-values obtained comparing PBC pts with control cohorts are shown:  
**** P < 0,0001; ** P 0.001 to 0.01 . 
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CONCLUSIONS 
PBC is one of the few AID having available a not-invasive diagnostic tool, i.e. serum AMA detection. 
However, since AMA are not present in all pts, the diagnostic procedure includes also a control of 
alkaline phosphatase elevation, and/or histological analyses on bioptic tissue135. AMA detection 
procedure is executed by IIF (a not-automated, subjective and labor-intensive technique) on whole 
tissues from rat kidney as Ag substrate. This enables the detection of a heterogeneous Ab 
population, directed against an undefined complex of various, not fully characterized proteins, the 
so-called M2 Ag. The absence of a precise molecular definition of the immunodominant epitope(s) 
led to an intricate situation, which results in a lack of characterization of the immunopathogenic 
mechanism triggering and pursuing PBC. Indeed, the research in the PBC field was strictly focused 
on the identification of the main immunogenic region of AMA, without considering that the 
diagnostic test reveals Ab toward a pool of proteins. 
In the late 80s, the main immunogenic region was mapped to the inner lipoyl domain of PDC-E2, 
and specifically to the Aa residues surrounding the lipoylated K173 of the linear peptide 
AEIETDKATIGFEVQEEG, corresponding to PDC-E2(167-184)153. Therefore, the importance of 
both lipoyl-Lys and lipoic acid per se were extensively debated, but without reaching a conclusion, 
particularly due to the use of inhomogeneous Ag preparations and sequences. Furthermore, some 
studies have not taken into account the lipoylation status of the probes, resulting in even more 
confusion. Even the conformational study performed by Howard et al.165, which resolved the 3D 
structure of recombinant hPDC-E2132-208 speculating the exposition of lipoic acid at the top of a 
tight type I β-turn (Figure 42), was performed without verifying the lipoylation status of the protein. 
This could have led to the obtainment of a structure that not correspond to the native one, as the 
presence of lipoic acid may influence both conformation and folding. To elucidate this point, 
circular dichroism spectroscopy studies on our synthetic peptides [(R/S)-Lipoamide-Lys173]PDC-
E2(167-186)-KKKK and [Lys173]PDC-E2(167-186)-KKKK were performed by Prof. Alfonso 
Carotenuto (University of Naples "Federico II"). Preliminary results disclosed that lipoylation 
actually affects the conformation of the peptides (data not shown), although it should be taken into 
account that peptides have a different conformational behavior compared with full-length proteins, 
encouraging us to deepen the structural differences between lipoylated and unlipoylated probes. 
In this context, we decided to clarify the situation characterizing PDC-E2 immunodominat region 
(Aa 167-184) from a molecular point of view. We focused our attention on both lipoylation and 
aberrant PTM that may occur on this region, using well-defined synthetic hPDC-E2 peptide probes, 
which were used as antigenic probes in SP-ELISA to detect Ab in PBC pts sera.  
Firstly, we examined the problem of lipoic acid chirality, which until now was never addressed. We 
elucidated that the chirality on the C6 has no influence on the Ab recognition, as the Ab responses 
detected toward (R)- and (S)-enantiomers are comparable.  
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Secondly, we clarified the relevance of K173 lipoylation and hypothetical exposition on the β-turn in 
the Ab recognition inserting it on the tip of a optimized scaffold β-turn peptide sequence, CSF114177. 
We tested analogues of CSF114, disclosing that the absorbance values observed against CSF114 
series are lower than the one obtained with the corresponding hPDC-E2 analogues. Based on these 
results, we speculate that Lys (both lipoylated and unlipoylated) exposed on the type I’ β-turn 
irrelevant peptide sequence is not able to detect Ab in PBC pts, and therefore that the Aa residues 
surrounding Lys are required for Ab recognition.  
Thirdly, as we previously demonstrated the involvement of aberrant N-glucosylation in 
autoimmunity and the role of Asn(Glc) as minimal epitope exposed on a type I’ β-turn structure36,37, 
we decided to explore the putative relevance of this PTM in PBC. Therefore, we tested an analog of 
hPDC-E2 peptide containing the minimal epitope Asn(Glc) exposed on the tip of the β-turn (same 
position of the natural lipoylated Lys). Results were compared with the unglucosylated analogue 
(bearing a Lys → Asn mutation), uncovering the hypothesis of an involvement of aberrant N-
glucosylation in the immunopathogenesis of PBC. The specificity of the response against Glc was 
assessed testing a peptide bearing a GlcNAc on Asn residue, which gave lower titers compared with 
Glc peptide. These results allow us to assume the presence of a Glc-specific response in PBC sera. 
We investigated also the possibility of a role of Asn(Glc) independently from the specific sequence 
of hPDC-E2 testing analogues of CSF114. Preliminary data display a high and specific response in 
the case of [Asn173(Glc)]PDC-E2(167-186)-KKKK, uncovering the hypothesis of an involvement of 
aberrant N-glucosylation in the immunopathogenesis of PBC, which however requires further 
clarification. 
 
In addition to the molecular characterization of the PDC-E2 immunodominant region, we 
evaluated the possible diagnostic relevance of the previously mentioned peptides, in order to 
identify auto-Ab in pts sera as disease BM (summarized in Table 6). For this purpose, we tested the 
synthetic probes as Ag in SP-ELISA, comparing the results obtained in the PBC cohort with other 
control diseases, such as RA, SSC, OAID and NBD. Disease-specificity of the detected Ab was 
evaluated comparing the results obtained in PBC pts with NBD cohort using a cutoff value 
calculated as (mean value of NBD) + 3*(standard deviation of NBD). Comparing PBC data with 
NBD through cutoff value allowed us to identify [Lys173]PDC-E2(167-186)-KKKK as the most 
relevant antigenic probe for IgM detection. This peptide recognized 63% of PBC pts sera, even if 
with lower titers compared with the lipoylated peptide [(R)-Lipoamide-Lys173]PDC-E2(167-186)-
KKKK, which is able to discriminate 37% of pts. PBC-specificity of the detected Ab was confirmed 
using pathologic control cohorts: we obtained 0% positivity percentage for IgM against the 
unlipoylated PDC-E2 peptide in both RA and SSC cohorts, while OAID have 23% of positivity.  
Based on the obtained results, we hypothesized that an aberrant PTM, namely a de-lipoylation, may 
uncover a neo-epitope, triggering PBC autoimmune reaction. Inner mitochondrial proteins may 
become the target of an autoimmune response by several possible mechanisms, including 
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abnormalities in structure: altered or abnormal enzyme forms may be degraded at an increased 
rate, leading to amplified presentation at the surface. 
The de-lipoylation reaction may be enzymatically performed by a lipoamidase (Lpa). For example, 
the presence of an Lpa was described in Enterococcus faecalis, a gut bacterium capable to do a 
commensal-to-pathogen switch in particular conditions. Expression and cloning of Lpa allowed to 
demonstrate its ability to release lipoyc acid from lipoylated intact proteins both in vivo and in 
vitro178,179. Intriguingly, Enterococcus faecalis is responsible of urinary tract infections, and the 
occurrence of this pathology is strictly associated with PBC as reproducible risk factor180,181. Based 
on these observations, it is possible to hypothesize the occurrence of a pathological de-lipoylation 
of PDC-E2 operated by Enterococcus faecalis as trigger for PBC. 
Even if hPDC-E2 includes two lipoyl domains (Figure 52), a de-lipoylation of the protein could lead 
to a failure of the PDC function or even to an enzymatic inactivation. Genetic PDC-E2 deficiency 
results in lactic acidosis as well as neurological dysfunction in infancy and early childhood182, 
symptoms that are not included in the clinical presentation of PBC pts. 
 
 
 
Figure 52: PDC-E2 domains in different species: E.coli, mammals, yeast. 
 
However, both Van de Water183 and Uibo184 demonstrated the AMA ability to inhibit the catalytic 
function of PDC by binding to the residues surrounding the lipoyl-Lys on PDC-E2, which is the core 
of the enzymatic reaction. Specifically, they incubated PBC pts sera with commercial PDC in a 
medium containing the reagents required for the enzymatic reaction, and quantified the NADH 
production by spectrophotometrical measurement at 340 nm. Intriguingly, the degree of enzymatic 
inhibition was directly proportional to the pts ABS value detected in ELISA. It was also 
demonstrated that PBC pts sera pre-absorbed with the recombinant Ag lost the ability to inhibit 
the enzyme activity. Results obtained with control sera are comparable with the one achieved 
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incubating the reaction mixture without sera. Therefore, the presence of AMA per se affects the 
enzyme functionality. Based on this statement, it is possible to hypothesize that the presence of an 
aberrant modification on PDC-E2, which may lead to an enzyme malfunction, is compatible with 
the disorder.  
Testing [Lys173]PDC-E2(167-186)-KKKK, we obtained 63% of positivity in PBC pts, which may seem 
a relatively significant result compared with the 95% detected by the routine assay. However, it 
must be kept in mind that the IIF assay measures the response directed toward a mixture of tissue 
Ag trough a complicated and time-consuming method. Our simple, single-Ag detection enabled to 
identify a population of PBC pts, with high specificity compared with control cohorts. Indeed, the 
significance of our result is emphasized not only by the 0% positivity obtained testing NBD, RA and 
SSC control cohorts, but also by the fact that RA is characterized by high levels cross-reactive Ab, 
and SSC is often associated with PBC. It will be of great interest to investigate the clinical features 
of the positive pts compared with the negative one, to disclose if our assay is able to discriminate a 
clinically defined subgroup of PBC pts, characterized by pathological peculiarity. Further 
investigations will be carried out to identify other candidate Ag to be added to the selected one, in 
order to develop a multi-Ag assay capable to discriminate a higher percentage of pts. In this way, 
we may obtain a new diagnostic tool characterized by: 
 Molecular characterization of the Ag; 
 Low invasivity for the pts; 
 Ease of execution (with feasibility of automating) and high reproducibility of the assay, 
which gave clearly interpretable results. 
Concluding, these results allowed us to hypothesize a molecular mechanism responsible for PBC 
triggering, and pave the way for further studies aimed both at understanding the pathological 
insights of PBC and at developing a more advantageous and significant diagnostic assay. 
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MATERIALS & METHODS 
Serum samples 
50 AMA+ and 15 AMA- serum samples were analyzed as PBC pts group (n=65). 56 NBD serum 
samples were used as healthy control group. Samples were tested in triplicate with a single dilution 
(1:100) in FBS Buffer.  
 
Antigens 
Antigenic probes used in this study are listed in Table 6. All the sequences were synthesized at the 
SOSCO Laboratory (Universitè de Cergy Pontoise, France) using SPPS strategy.  
 
Enzyme-Linked Immunosorbent Assay (ELISA) 
1ug/well of Ag (peptide or protein) were dissolved in Coating Buffer (12mM Na2CO3, 35mM 
NaHCO3, pH 9.6), then 100 ul of solution were dispensed in each well of 96-well Maxisorp plates. 
Plates were incubated @4°C ON. Subsequently, plates were washed 3 times with Washing Buffer 
(0,9% NaCl, 0,01% Tween 20), and blocked 1 h at RT with 100ul/well of FBS Buffer (10% FBS in 
Washing Buffer). FBS Buffer were removed, and 100ul/well of diluted sera sample (1:100 in FBS 
Buffer) were dispensed. Blank wells were included in all the plates, and were obtained using FBS 
Buffer instead of serum. Plates were incubated @4°C ON, and then washed 3 times with Washing 
Buffer. 100ul/well of secondary Ab diluted in FBS Buffer (hIgG 1:8000 and hIgM 1:1200) were 
dispensed, and plates were incubated 3 h at RT. Plates were washed 3 times with Washing Buffer, 
then 100ul/well of Substrate Solution (1mg/ml p-PNP in Substrate Buffer: 1M Diethanolamine, 
1mM MgCl2, pH 9.8) were dispensed. Plates were incubated for 15’-40’, and then ABS at 405 nm 
of each well was red with a spectrophotometer. ABS value for each serum was calculated as (mean 
ABS of triplicate) – (mean ABS of blank triplicate).  
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SUPPLEMENTARY DATA 
 
 
 
Supplementary figure 1: IgM data distribution of PBC pts and control cohorts  
against PDC-E2 peptides. Dotted line indicate the cutoff value.  
P-values obtained comparing PBC pts with control cohorts are shown:  
**** P < 0,0001; *** P 0.0001 to 0.001; ** P 0.001 to 0.01; * P 0.01 to 0.05. 
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Supplementary figure 2: IgG data distribution of PBC pts and control cohorts  
against PDC-E2 peptides. Dotted line indicate the cutoff value.  
P-values obtained comparing PBC pts with control cohorts are shown:  
**** P < 0,0001; *** P 0.0001 to 0.001; ** P 0.001 to 0.01; * P 0.01 to 0.05. 
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ABBREVIATIONS 
AID Autoimmune Disease Ig Immunoglobulin 
Aa Aminoacid IIF Indirect Immunofluorescence 
Ab Antibody K Lys 
ABS Absorbance kDa kilo Daltom 
Ag Antigen mAb Monoclonal Ab 
AMA  Anti-Mitochondrial Antibodies MBP Myelin Basic Protein 
APC  Antigen Presenting Cell MHC Major Histocompatibility Complex  
AQP4 Aquaporin-4 MOG Myelin Oligodendrocyte Glycoprotein 
BCKD-E2 Dehydrogenase Dihydrolipoyl Transacylase  mRNA Messenger RNA 
BM Biomarker MS Multiple Sclerosis 
BSA Bovine Serum Albumin NBD Normal Blood Donors 
C.jejuni Campylobacter jejuni  NCL Native Chemical Ligation 
cDNA Complementary DNA NMO Neuromyelitis Optice 
CDR Complementarity Determining Regions  OD Optical Density 
CIS Clinically Isolated Syndrome OGDC-E2 Dihydrolipoamide Succinyltransferase  
CNS Central Nervous System OND Other Neurological Disorders 
CSF Cerebrospinal Fluid OVA Ovalbumin 
E.coli Escherichia coli PBC Primary Biliary Cirrhosis 
E3BP Dihydrolipoamide Dehydrogenase Binding Protein PDC-E2 Dihydrolipoamide Acetyltransferase  
EAE Experimental Autoimmune Encephalomyelitis  PPMS Primary Progressive MS 
ELISA Enzyme-Linked Immunosorbent Assay PTM Post-Translational Modification 
FACS Fluorescence-Activated Flow Cytometry  pts Patients 
FBS Fetal Bovine Serum RA Rheumatoid Arthritis 
Glc Glucose RRMS Relapsing-Remitting MS 
GlcNAc N-Acetyl-Glucosamine  SLE Systemic Lupus Erytemathosus 
GWAS Genome-Wide Association Studies SP-ELISA Solid Phase ELISA 
H.infulenzae Haemophilus influenzae SPMS Secondary Progressive MS 
HIBEC Human Intrahepatic Biliary Epithelium Cells  SPPS Solid-Phase Peptide Synthesis 
HLA Human Leukocyte Antigen SSC Scleroderma 
HMW1 High-Molecular-Weight Adhesin 1  TEV Tobacco Etch Virus  
IB  Inclusion Bodies ul microliter 
 
